1
|
Xiang L, Graves N, Low AHL, Leung YY, Fong W, Gan WH, Gandhi M, Thumboo J. Cost of lost productivity in inflammatory arthritis and osteoarthritis in the year before and after diagnosis: An inception cohort study. Int J Rheum Dis 2024; 27:e15252. [PMID: 38982887 DOI: 10.1111/1756-185x.15252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Revised: 11/17/2023] [Accepted: 06/21/2024] [Indexed: 07/11/2024]
Abstract
AIM Existing studies on the cost of inflammatory arthritis (IA) and osteoarthritis (OA) are often cross-sectional and/or involve patients with various disease durations, thus not providing a comprehensive perspective on the cost of illness from the time of diagnosis. In this study, we therefore assessed the cost of lost productivity in an inception cohort of patients with IA and OA in the year before and after diagnosis. METHODS Employment status, monthly income, days absent from work, and presenteeism were collected at diagnosis and 1 year later to estimate the annual costs of unemployment, absenteeism, and presenteeism using human capital approach. Non-parametric bootstrapping was performed to account for the uncertainty of the estimated costs. RESULTS Compared to patients with OA (n = 64), patients with IA (n = 102, including 48 rheumatoid arthritis, 19 spondyloarthritis, 23 psoriatic arthritis, and 12 seronegative IA patients) were younger (mean age: 52.3 vs. 59.5 years) with a greater proportion receiving treatment (99.0% vs. 67.2%) and a greater decrease in presenteeism score (median: 15% vs 10%) 1 year after diagnosis. Annual costs of absenteeism and presenteeism were lower in patients with IA than those with OA both in the year before (USD566 vs. USD733 and USD8,472 vs. USD10,684, respectively) and after diagnosis (USD636 vs. USD1,035 and USD6,866 vs. USD9,362, respectively). CONCLUSION Both IA and OA impose substantial cost of lost productivity in the year before and after diagnosis. The greater improvement in productivity seen in patients with IA suggests that treatment for IA improves work productivity.
Collapse
Affiliation(s)
- Ling Xiang
- Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
| | - Nicholas Graves
- Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore
| | - Andrea H L Low
- Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- Duke-NUS Medical School, Singapore, Singapore
| | - Ying-Ying Leung
- Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- Duke-NUS Medical School, Singapore, Singapore
| | - Warren Fong
- Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- Duke-NUS Medical School, Singapore, Singapore
| | - Wee-Hoe Gan
- Duke-NUS Medical School, Singapore, Singapore
- Department of Occupational and Environmental Medicine, Singapore General Hospital, Singapore, Singapore
| | - Mihir Gandhi
- Biostatistics, Singapore Clinical Research Institute, Singapore, Singapore
- Centre of Quantitative Medicine, Duke-NUS Medical School, Singapore, Singapore
- Tampere Center for Child Health Research, Tampere University, Tampere, Finland
| | - Julian Thumboo
- Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- Duke-NUS Medical School, Singapore, Singapore
| |
Collapse
|
2
|
Pascual-Ramos V, Contreras-Yáñez I, Cuevas-Montoya M, Guaracha-Basañez GA, García-Alanis M, Rodríguez-Mayoral O, Chochinov HM. Factors Associated With Distress Related to Perceived Dignity in Patients With Rheumatic Diseases. J Clin Rheumatol 2024; 30:e115-e121. [PMID: 38595276 DOI: 10.1097/rhu.0000000000002083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/11/2024]
Abstract
BACKGROUND The loss of perceived dignity is an existential source of human suffering, described in patients with cancer and chronic diseases and hospitalized patients but rarely explored among patients with rheumatic diseases (RMDs). We recently observed that distress related to perceived dignity (DPD) was present in 26.9% of Mexican patients with different RMDs. The study aimed to investigate the factors associated with DPD. METHODS This cross-sectional study was performed between February and September 2022. Consecutive patients with RMDs completed patient-reported outcomes (to assess mental health, disease activity/severity, disability, fatigue, quality of life [QoL], satisfaction with medical care, and family function) and had a rheumatic evaluation to assess disease activity status and comorbidity. Sociodemographic variables and disease-related and treatment-related variables were retrieved with standardized formats. DPD was defined based on the Patient Dignity Inventory score. Multivariate regression analysis was used. RESULTS Four hundred patients were included and were representative of outpatients with RMDs, while 7.5% each were inpatients and patients from the emergency care unit. There were 107 patients (26.8%) with DPD. Past mental health-related comorbidity (Odds Ratio [OR]: 4.680 [95% Confidence Interval [CI]: 1.906-11.491]), the number of immunosuppressive drugs/patient (OR: 1.683 [95% CI: 1.015-2.791]), the physical health dimension score of the World Health Organization Quality of Life-Brief questionnaire (WHOQOL-BREF) (OR: 0.937 [95% CI: 0.907-0.967]), and the emotional health dimension score of the WHOQOL-BREF (OR: 0.895 [95% CI: 0.863-0.928]) were associated with DPD. CONCLUSIONS DPD was present in a substantial proportion of patients with RMDs and was associated with mental health-related comorbidity, disease activity/severity-related variables, and the patient QoL.
Collapse
Affiliation(s)
- Virginia Pascual-Ramos
- From the Department of Immunology and Rheumatology. Instituto Nacional de Ciencias Médicas y Nutrición Salvador-Zubirán (INCMyN-SZ), Mexico City, Mexico
| | - Irazú Contreras-Yáñez
- From the Department of Immunology and Rheumatology. Instituto Nacional de Ciencias Médicas y Nutrición Salvador-Zubirán (INCMyN-SZ), Mexico City, Mexico
| | - Maximiliano Cuevas-Montoya
- From the Department of Immunology and Rheumatology. Instituto Nacional de Ciencias Médicas y Nutrición Salvador-Zubirán (INCMyN-SZ), Mexico City, Mexico
| | - Guillermo Arturo Guaracha-Basañez
- From the Department of Immunology and Rheumatology. Instituto Nacional de Ciencias Médicas y Nutrición Salvador-Zubirán (INCMyN-SZ), Mexico City, Mexico
| | - Mario García-Alanis
- Department of Psychiatry. Instituto Nacional de Ciencias Médicas y Nutrición Salvador-Zubirán (INCMyN-SZ, Mexico City, Mexico
| | | | - Harvey Max Chochinov
- Department of Neurology and Psychiatry, University of Manitoba, Cancer Care Manitoba, Winnipeg, Canada
| |
Collapse
|
3
|
Haroutounian S, Holzer KJ, Kerns RD, Veasley C, Dworkin RH, Turk DC, Carman KL, Chambers CT, Cowan P, Edwards RR, Eisenach JC, Farrar JT, Ferguson M, Forsythe LP, Freeman R, Gewandter JS, Gilron I, Goertz C, Grol-Prokopczyk H, Iyengar S, Jordan I, Kamp C, Kleykamp BA, Knowles RL, Langford DJ, Mackey S, Malamut R, Markman J, Martin KR, McNicol E, Patel KV, Rice AS, Rowbotham M, Sandbrink F, Simon LS, Steiner DJ, Vollert J. Patient engagement in designing, conducting, and disseminating clinical pain research: IMMPACT recommended considerations. Pain 2024; 165:1013-1028. [PMID: 38198239 PMCID: PMC11017749 DOI: 10.1097/j.pain.0000000000003121] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 08/31/2023] [Accepted: 09/08/2023] [Indexed: 01/12/2024]
Abstract
ABSTRACT In the traditional clinical research model, patients are typically involved only as participants. However, there has been a shift in recent years highlighting the value and contributions that patients bring as members of the research team, across the clinical research lifecycle. It is becoming increasingly evident that to develop research that is both meaningful to people who have the targeted condition and is feasible, there are important benefits of involving patients in the planning, conduct, and dissemination of research from its earliest stages. In fact, research funders and regulatory agencies are now explicitly encouraging, and sometimes requiring, that patients are engaged as partners in research. Although this approach has become commonplace in some fields of clinical research, it remains the exception in clinical pain research. As such, the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials convened a meeting with patient partners and international representatives from academia, patient advocacy groups, government regulatory agencies, research funding organizations, academic journals, and the biopharmaceutical industry to develop consensus recommendations for advancing patient engagement in all stages of clinical pain research in an effective and purposeful manner. This article summarizes the results of this meeting and offers considerations for meaningful and authentic engagement of patient partners in clinical pain research, including recommendations for representation, timing, continuous engagement, measurement, reporting, and research dissemination.
Collapse
Affiliation(s)
- Simon Haroutounian
- Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO, United States
| | - Katherine J. Holzer
- Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO, United States
| | - Robert D. Kerns
- Departments of Psychiatry, Neurology, and Psychology, Yale University, New Haven, CT, United States
| | - Christin Veasley
- Chronic Pain Research Alliance, North Kingstown, RI, United States
| | - Robert H. Dworkin
- Department of Anesthesiology and Perioperative Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States
| | - Dennis C. Turk
- Department of Anesthesiology & Pain Medicine, University of Washington, Seattle, WA, United States
| | - Kristin L. Carman
- Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, United States
| | - Christine T. Chambers
- Departments of Psychology & Neuroscience and Pediatrics, Dalhousie University, and Centre for Pediatric Pain Research, IWK Health Centre, Halifax, NS, Canada
| | - Penney Cowan
- American Chronic Pain Association, Rocklin, CA, United States
| | - Robert R. Edwards
- Department of Anesthesiology, Harvard Medical School, Brigham & Women's Hospital, Boston, MA, United States
| | - James C. Eisenach
- Departments of Anesthesiology, Physiology and Pharmacology, Wake Forest University School of Medicine, Winston Salem, NC, United States
| | - John T. Farrar
- Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, United States
| | - McKenzie Ferguson
- Southern Illinois University Edwardsville, School of Pharmacy, Edwardsville, IL, United States
| | - Laura P. Forsythe
- Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, United States
| | - Roy Freeman
- Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, United States
| | - Jennifer S. Gewandter
- Department of Anesthesiology and Perioperative Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States
| | - Ian Gilron
- Departments of Anesthesiology & Perioperative Medicine and Biomedical & Molecular Sciences, Queen's University, Kingston, ON, Canada
| | - Christine Goertz
- Department of Orthopaedic Surgery, Duke University School of Medicine, Durham, NC, United States
| | | | - Smriti Iyengar
- Division of Translational Research, National Institute of Neurological Disorders and Stroke, Bethesda, MD, United States
| | - Isabel Jordan
- Departments of Psychology & Neuroscience and Pediatrics, Dalhousie University, and Centre for Pediatric Pain Research, IWK Health Centre, Halifax, NS, Canada
| | - Cornelia Kamp
- Center for Health and Technology/Clinical Materials Services Unit, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States
| | - Bethea A. Kleykamp
- Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, United States
| | - Rachel L. Knowles
- Medical Research Council (part of UK Research and Innovation), London, United Kingdom
| | - Dale J. Langford
- Department of Anesthesiology, Critical Care & Pain Management, Hospital for Special Surgery, New York, NY, United States
| | - Sean Mackey
- Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University Medical Center, Stanford, CA, United States
| | | | - John Markman
- Department of Neurosurgery, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States
| | - Kathryn R. Martin
- Aberdeen Centre for Arthritis and Musculoskeletal Health, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, Scotland, United Kingdom
| | - Ewan McNicol
- Massachusetts College of Pharmacy and Health Sciences, Boston, MA, United States
| | - Kushang V. Patel
- Department of Anesthesiology & Pain Medicine, University of Washington, Seattle, WA, United States
| | - Andrew S.C. Rice
- Pain Research, Department of Surgery and Cancer, Imperial College London, London, United Kingdom
| | - Michael Rowbotham
- Departments of Anesthesia and Neurology, University of California San Francisco, San Francisco, CA, United States
| | - Friedhelm Sandbrink
- National Pain Management, Opioid Safety, and Prescription Drug Monitoring Program, Specialty Care Program Office, Veterans Health Administration, Washington, DC, United States
| | | | - Deborah J. Steiner
- Global Pain, Pain & Neurodegeneration, Eli Lilly and Company, Indianapolis, IN, United States
| | - Jan Vollert
- Pain Research, Department of Surgery and Cancer, Imperial College London, London, United Kingdom
- Division of Neurological Pain Research and Therapy, Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel, Germany
- Department of Anaesthesiology, Intensive Care and Pain Medicine, University Hospital Muenster, Münster, Germany
- Department of Neurophysiology, Mannheim Center for Translational Neuroscience MCTN, Medical Faculty Mannheim, Ruprecht Karls University, Heidelberg, Germany
| |
Collapse
|
4
|
Brown T, Hammond A, Ching A, Parker J. Work limitations and associated factors in rheumatoid arthritis, axial spondyloarthritis, osteoarthritis and fibromyalgia. Musculoskeletal Care 2023; 21:827-844. [PMID: 36975543 DOI: 10.1002/msc.1760] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Accepted: 03/05/2023] [Indexed: 03/29/2023]
Abstract
INTRODUCTION Rheumatic and musculoskeletal diseases (RMD) impact on work participation. The aims of this study were to: examine work limitations of working people with: rheumatoid arthritis, axial spondyloarthritis (axSpA), osteoarthritis, or fibromyalgia using the Workplace Activity Limitations Scale (WALS, a measure of presenteeism); and identify personal, functioning and disability, and work contextual factors associated with presenteeism. METHODS Secondary analysis was conducted of a cross-sectional survey including work outcome measures (WORK-PROM study). A literature review identified variables (coded to ICF) to include in multivariable regressions examining factors associated with presenteeism. RESULTS Moderate to high WALS scores were identified in: 93.60% with FM; 69.90% OA; 65.20% RA; and 46.80% axSpA (n = 822). Similarities in work limitations were noted across conditions, although some more problematic in specific RMD. Participants received help with about a quarter of activities (27%RA; 25%FM; 23%OA; 17%axSpA) and work adaptations for less than a fifth causing difficulty (18%FM; 14%RA; 14%OA; 9%axSpA). Literature review identified 33 variables in the WORK-PROM dataset to include in multivariable regressions. Factors associated with higher WALS scores were worse: functional limitations, job strain, pain, difficulties with mental-interpersonal job demands, perceived health status, work-life balance, greater need for work accommodations and lack of perceived work support. DISCUSSION This study extends understanding of work limitations of working people with these four RMD, the extent of help and adaptations received, need for more work accommodation support, and focus on work support, work rehabilitation, and healthy workplace practices to help keep people working.
Collapse
Affiliation(s)
- Tamara Brown
- Centre for Human Movement and Rehabilitation Research, School of Health and Society, University of Salford, Salford, Greater Manchester, UK
| | - Alison Hammond
- Centre for Human Movement and Rehabilitation Research, School of Health and Society, University of Salford, Salford, Greater Manchester, UK
| | - Angela Ching
- Centre for Human Movement and Rehabilitation Research, School of Health and Society, University of Salford, Salford, Greater Manchester, UK
- King's Clinical Trials Unit, Institute of Psychiatry, Kings College London, London, UK
| | - Jennifer Parker
- Centre for Human Movement and Rehabilitation Research, School of Health and Society, University of Salford, Salford, Greater Manchester, UK
| |
Collapse
|
5
|
L'Heureux J, McTaggart-Cowan H, Johns G, Chen L, Steiner T, Tocher P, Sun H, Zhang W. How to present work productivity loss results from clinical trials for patients and caregivers? A mixed methods approach. Soc Sci Med 2023; 328:115999. [PMID: 37276772 DOI: 10.1016/j.socscimed.2023.115999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Revised: 05/23/2023] [Accepted: 05/26/2023] [Indexed: 06/07/2023]
Abstract
OBJECTIVES From the perspectives of patients and caregivers, the objectives were: identifying which result presentations, describing work productivity loss (WPL) outcomes, are most understandable; measuring which presentations are important to report; and investigating which WPL outcomes are viewed as important alongside clinical trials results. METHODS We used a four phased, sequential mixed methods design, guided by patient-oriented research engaging one patient partner. We conducted think-aloud interviews, in British Columbia/Canada, to review WPL results and our survey measuring the understandability and importance of the results, and importance of each WPL outcome. We surveyed a sample representing working Canadians. The findings were summarized and analyzed using linear and logistic regression. We conducted sub-group analyses; one was gender based. All regressions were conducted using generalized estimating equations. RESULTS In our qualitative phases, 20 patients and caregivers were interviewed. Participants recommended for the results to be brief, simple, and represented visually. Then, 118 patients and 120 caregivers were surveyed. The results presented in days or cost yielded the highest understandability and importance to report. All WPL outcomes were identified as important to somewhat important to report by most. The associations indicated that the more understandable the result presentation was, the more likely it was to be rated as important. Age was the only factor significantly associated with selecting days or cost as the most important result. CONCLUSION Presenting WPL results in days and cost, using lay terms and visual supports, were viewed as easiest to understand and most important to report in clinical trials by patients and caregivers. Our findings are supportive of clinical trials standardizing the measurement of WPL to include all of its outcomes (absenteeism, presenteeism, employment status changes and total work productivity loss), in addition to tools assessing the comprehensiveness of WPL results to be provided to patients and caregivers.
Collapse
Affiliation(s)
- Jacynthe L'Heureux
- School of Population and Public Health, University of British Columbia; 2206 E Mall, Vancouver, British Columbia, V6T 1Z3, Canada.
| | - Helen McTaggart-Cowan
- Faculty of Health Sciences, Simon Fraser University; Blusson Hall, Room, 11300, 8888 University Drive, Burnaby, British Columbia, V5A 1S6, Canada; British Columbia Cancer Research Centre, 675 W 10th Avenue; Vancouver, British Columbia, V5Z 1L3, Canada.
| | - Gary Johns
- Sauder School of Business, University of British Columbia; 2053 Main Mall, Vancouver, British Columbia, V6T 1Z2, Canada; John Molson School of Business, Concordia University, 1450 Guy Street, Montreal, Quebec, H3H 0A1, Canada.
| | - Lin Chen
- Patient Voices Network, 201-750 Pender Street, Vancouver, British Columbia, V6C 2T8, Canada
| | - Theodore Steiner
- Division of Infectious Diseases, Vancouver General Hospital, 2733 Heather Street, Rm C328 HP East, Vancouver, British Columbia, V5Z 3J5, Canada.
| | - Paige Tocher
- Centre for Health Evaluation and Outcome Sciences, 570-1081 Burrard Street, Vancouver, British Columbia, V6Z 1Y6, Canada
| | - Huiying Sun
- Centre for Health Evaluation and Outcome Sciences, 570-1081 Burrard Street, Vancouver, British Columbia, V6Z 1Y6, Canada.
| | - Wei Zhang
- School of Population and Public Health, University of British Columbia; 2206 E Mall, Vancouver, British Columbia, V6T 1Z3, Canada; Centre for Health Evaluation and Outcome Sciences, 570-1081 Burrard Street, Vancouver, British Columbia, V6Z 1Y6, Canada; Faculty of Pharmaceutical Sciences, University of British Columbia; 2405 Wesbrook Mall, Vancouver, British Columbia, V6T 1Z3, Canada.
| |
Collapse
|
6
|
Gorial FI, Awadh NI, Humadi YA, Mutar MT, Hameed MM, Ali SB, Hasan HF, Aljafr AN. A 5 item version of the Workplace Activity Limitation Scale successfully identifies impaired work productivity in rheumatoid arthritis patients: A split-sample factor analysis approach. Int J Rheum Dis 2023; 26:501-509. [PMID: 36722751 DOI: 10.1111/1756-185x.14584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Revised: 01/07/2023] [Accepted: 01/13/2023] [Indexed: 02/02/2023]
Abstract
BACKGROUND There is a growing interest in studying the effects of arthritis on a person's work productivity using a growing variety of outcome indicators. OBJECTIVES To develop a valid and reliable shortened version of the Workplace Activity Limitation Scale 12 (WALS-12) for assessing work productivity limitations in rheumatoid arthritis (RA) patients. METHODS A cross-sectional study involving 277 RA patients was conducted. An exploratory factor analysis on WALS-12 was used for item reduction on the first sample. Then confirmatory factor analysis (CFA) was run to establish the best fit indices of the reduced version. On the second sample, CFA and linear discriminant analysis were performed to assess the diagnostic performance and discriminant ability of the reduced form. A Bland-Altman method was used to find the agreement between the WALS-12 and the reduced one. RESULTS The WALS-12 was reduced to 5 items. The Cronbach α was 0.817, with a composite reliability of 0.715. The Spearman rho correlation coefficient ranged between 0.675 and 0.795 for WALS-5, which was higher for the scale items with their domains than the correlation of WALS-5 with the domains of Work Limitations Questionnaire-25. Also, the root square of the average variant extracted from WALS-5 was 0.802. WALS-5 showed excellent discriminant ability with an area under the curve of 0.98 (P < .001), sensitivity of 97%, specificity of 82%, and accuracy of 94%. The reduced version WALS-5 was in agreement with the original version WALS-12. CONCLUSIONS WALS-5 is a valid and reliable tool to assess the work productivity limitations in RA patients.
Collapse
Affiliation(s)
- Faiq I Gorial
- Rheumatology Unit, Department of Internal Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq
| | - Nabaa Ihsan Awadh
- Rheumatology Unit, Department of Internal Medicine, Baghdad Teaching Hospital, Baghdad, Iraq
| | - Yasameen Abbas Humadi
- Rheumatology Unit, Department of Internal Medicine, College of Medicine, Al-Nahrain University, Baghdad, Iraq
| | - Mohammed Tareq Mutar
- Department of Surgery, College of Medicine, University of Baghdad, Baghdad, Iraq
| | - Mustafa Majid Hameed
- Department of Internal Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq
| | - Shahlaa B Ali
- Rheumatology Unit, Department of Internal Medicine, Baghdad Teaching Hospital, Baghdad, Iraq
| | - Hala Fadhil Hasan
- Rheumatology Unit, Department of Internal Medicine, Baghdad Teaching Hospital, Baghdad, Iraq
| | - Alyaa N Aljafr
- Rheumatology Unit, Department of Internal Medicine, Baghdad Teaching Hospital, Baghdad, Iraq
| |
Collapse
|
7
|
Zhang W, Tocher P, L'Heureux J, Sou J, Sun H. Measuring, Analyzing, and Presenting Work Productivity Loss in Randomized Controlled Trials: A Scoping Review. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2023; 26:123-137. [PMID: 35961865 DOI: 10.1016/j.jval.2022.06.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Revised: 05/14/2022] [Accepted: 06/08/2022] [Indexed: 06/15/2023]
Abstract
OBJECTIVES This study aimed to conduct a scoping review of randomized controlled trials (RCTs) and investigate which work productivity loss outcomes were measured in these RCTs, how each outcome was measured and analyzed, and how the results for each outcome were presented. METHODS A systematic search was conducted from January 2010 to April 2020 from 2 databases: PubMed and Cochrane Central Register of Controlled Trials. Data on country, study population, disease focus, sample size, work productivity loss outcomes measured (absenteeism, presenteeism, employment status changes), and methods used to measure, report, and analyze each work productivity loss outcome were extracted and analyzed. RESULTS We found 435 studies measuring absenteeism or presenteeism, of which 155 studies (35.6%) measured both absenteeism and presenteeism and were included in our final review. Only 9 studies also measured employment status changes. The most used questionnaire was the Work Productivity and Activity Impairment Questionnaire. The analysis of absenteeism and presenteeism data was mostly done using regression models (n = 98, n = 98, respectively) for which a normal distribution was assumed (n = 77, n = 89, respectively). Absenteeism results were most often presented in time whereas presenteeism was commonly presented using a percent scale or score. CONCLUSIONS There is a lack of consensus on how to measure, analyze, and present work productivity loss outcomes in RCTs published in the past 10 years. The diversity of measurement, analysis, and presentation methods used in RCTs may make comparability challenging. There is a need for guidelines providing recommendations to standardize the comprehensiveness and the appropriateness of methods used to measure, analyze, and report work productivity loss in RCTs.
Collapse
Affiliation(s)
- Wei Zhang
- School of Population and Public Health, The University of British Columbia, Vancouver, BC, Canada; Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada.
| | - Paige Tocher
- Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada
| | - Jacynthe L'Heureux
- School of Population and Public Health, The University of British Columbia, Vancouver, BC, Canada
| | - Julie Sou
- Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada
| | - Huiying Sun
- Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada
| |
Collapse
|
8
|
Ravinskaya M, Verbeek JH, Langendam MW, Madan I, Verstappen SMM, Kunz R, Hulshof CTJ, Hoving JL. Preferred Methods of Measuring Work Participation: An International Survey Among Trialists and Cochrane Systematic Reviewers. JOURNAL OF OCCUPATIONAL REHABILITATION 2022; 32:620-628. [PMID: 35347539 PMCID: PMC9668767 DOI: 10.1007/s10926-022-10031-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 02/14/2022] [Indexed: 06/14/2023]
Abstract
Purpose Heterogeneity in work participation (WP) outcomes measurements hampers large scale evidence synthesis in systematic reviews of trials. In this survey we explore authors' reasons for choosing specific WP outcomes and their measurement methods, including employment status, absence from work, at-work productivity loss, and employability. Methods We contacted authors of 260 trials and 69 systematic reviews and asked closed and open-ended questions about previously used WP outcomes and measurement methods as well as their opinion on the best way to measure WP. Results In total, 91 authors from a wide range of professional backgrounds completed the survey. The majority of authors (86%) chose WP outcomes based on their use in previous similar studies. In most studies (88%), patients had not been involved in the process of selecting the WP outcome. Authors judged feasibility to be an important factor for choosing a measurement instrument (67%). Additionally, valid measurement tools should be available, easy to administer and not too time consuming. Although authors preferred registry data for long term follow-up, the availability and validity of registries was seen as a barrier. Most of the reviewers (72%) struggled to pool data because of variation in follow-up times and cut off points and varying definitions of work outcomes. Almost all (92%) respondents support the use of a Core Outcome Set for Work. Conclusions There is strong support from authors of trials and systematic reviews to develop a core outcome set on work participation outcomes for the evaluation of interventions.
Collapse
Affiliation(s)
- Margarita Ravinskaya
- Amsterdam UMC, Academic Medical Center, University of Amsterdam, Coronel Institute of Occupational Health, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
| | - Jos H Verbeek
- Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Coronel Institute of Occupational Health, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands
| | - Miranda W Langendam
- Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Department Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands
| | - Ira Madan
- Guy's and St Thomas' NHS Trust and Faculty of Life Sciences and Medicine, King's College London, Centre for Musculoskeletal Health and Work, London, UK
| | - Suzanne M M Verstappen
- Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
- NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
- MRC Versus Arthritis Centre for Musculoskeletal Health and Work, University of Southampton, Southampton, UK
| | - Regina Kunz
- Academic Unit EbIM, Evidence Based Insurance Medicine, Department of Clinical Research, University of Basel, Basel, Switzerland
| | - Carel T J Hulshof
- Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Coronel Institute of Occupational Health, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands
| | - Jan L Hoving
- Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Coronel Institute of Occupational Health, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands
| |
Collapse
|
9
|
A general framework for selecting work participation outcomes in intervention studies among persons with health problems: a concept paper. BMC Public Health 2022; 22:2189. [DOI: 10.1186/s12889-022-14564-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Accepted: 11/07/2022] [Indexed: 11/27/2022] Open
Abstract
Abstract
Background
Work participation is important for health and can be considered as engagement in a major area of life which is of significance for most people, but it can also be thought of as fulfilling or discharging a role. Currently, academic research lacks a comprehensive classification of work participation outcomes. The International Classification of Functioning is the foremost model in defining work functioning and its counterpart work disability, but it does not provide a critical (core) set of outcomes. Standardizing the definitions and nomenclature used in the research of work participation would ensure that the outcomes of studies are comparable, and practitioners and guideline developers can better decide what works best. As work participation is a broad umbrella term including outcome categories which need unambiguous differentiation, a framework needs to be developed first.
Aim
To propose a framework which can be used to develop a generic core outcome set for work participation.
Methods
First, we performed a systematic literature search on the concept of (work) participation, views on how to measure it, and on existing classifications for outcome measurements. Next, we derived criteria for the framework and proposed a framework based on the criteria. Last, we applied the framework to six case studies as a proof of concept.
Results
Our literature search provided 2106 hits and we selected 59 studies for full-text analysis. Based on the literature and the developed criteria we propose four overarching outcome categories: (1) initiating employment, (2) having employment, (3) increasing or maintaining productivity at work, and (4) return to employment. These categories appeared feasible in our proof-of-concept assessment with six different case studies.
Conclusion
We propose to use the framework for work participation outcomes to develop a core outcome set for intervention studies to improve work participation.
Collapse
|
10
|
Tański W, Dudek K, Adamowski T. Work Ability and Quality of Life in Patients with Rheumatoid Arthritis. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2022; 19:13260. [PMID: 36293837 PMCID: PMC9603111 DOI: 10.3390/ijerph192013260] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/21/2022] [Revised: 10/10/2022] [Accepted: 10/11/2022] [Indexed: 06/16/2023]
Abstract
BACKGROUND Reduced work participation has social implications (sickness absence, economic impact) and consequences for the individual patient (impoverishment, depression, limited social interaction). As patients with rheumatoid arthritis (RA) are more likely to experience job loss and/or at-work productivity loss and are at higher risk of sickness absence and, ultimately, permanent work productivity, consideration should be given to the association between work productivity or partial work capacity and quality of life (QoL). The aim of the study was to assess the relationship between QoL and the risk of work disability, as well as to estimate the risk of a future event and identify factors affecting the risk of work disability in RA inpatients. MATERIAL AND METHODS This cross-sectional study included 142 inpatients (65 male) aged 47 (38-58) years, who met the established criteria for a diagnosis of RA and treatment with biologic drugs. Only standardized tools were used to examine the patients: WHOQOL-BREF, MFIS and AS-WIS. RESULTS An analysis of the QoL scores on the WHOQOL-BREF demonstrated that the patients' QoL was lowest in the physical health domain and highest in the social relationships domain. The median WHOQOL-BREF total score in the group studied was 62.8, which indicates a moderate QoL. The median total score for the risk of work disability (AS-WIS) was 10.1, which indicates that the level of risk of work disability in the patients was higher than the average level reported in the literature. A multivariate analysis showed that the following were significant independent determinants of a higher risk of work disability: low QoL in the WHOQOL-BREF physical health (β = 0.961; p = 0.029) and psychological health (β = 1.752; p = 0.002) domains, being in a relationship (β = 0.043; p = 0.005) and the use of opioids for pain (β = 3.054; p = 0.012). CONCLUSIONS RA patients presented with moderate QoL, moderate fatigue (MFIS) and high risk of disability (AS-WIS). There is an association between a high risk of work disability and lower QoL, especially in the physical and psychological health domains. The lower the QoL in those domains, the higher the risk of work disability. The identification of factors increasing the risk of work disability will help in planning tailored interventions to improve at-work productivity loss and thus prevent work disability.
Collapse
Affiliation(s)
- Wojciech Tański
- Department of Internal Medicine, 4th Military Teaching Hospital, R. Weigla 5, 50-981 Wrocław, Poland
| | - Krzysztof Dudek
- Department of Transport Systems, Faculty of Mechanical Engineering, University of Technology, 50-370 Wrocław, Poland
| | - Tomasz Adamowski
- Department of Nursing and Obstetrics, Wroclaw Medical University, 51-618 Wrocław, Poland
| |
Collapse
|
11
|
Carvalho PD, Vieira-Sousa E, Hmamouchi I, Marreiros A, Machado PM. Determinants of health-related quality of life in spondyloarthritis and rheumatoid arthritis - data from the COMOSPA and COMORA studies. Semin Arthritis Rheum 2022; 57:152086. [DOI: 10.1016/j.semarthrit.2022.152086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2022] [Revised: 08/09/2022] [Accepted: 08/22/2022] [Indexed: 11/28/2022]
|
12
|
Poole JL. Beyond the hand and upper extremity: The role of hand therapists in care of people with rheumatic diseases. J Hand Ther 2022; 35:339-345. [PMID: 35985938 DOI: 10.1016/j.jht.2022.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/25/2022] [Revised: 06/23/2022] [Accepted: 07/03/2022] [Indexed: 02/03/2023]
Abstract
STUDY DESIGN Invited Clinical Commentary BACKGROUND: Arthritis is one of the most frequently reported causes of disability in the United States and the prevalence is expected to increase in the coming decades. While many rheumatic diseases involve hand impairments, most are systemic and involve more than the musculoskeletal system. Functional and work disability are high and people would benefit from the services of occupational and physical therapists. PURPOSE OF STUDY This paper reviews concepts of self-management, and symptoms that contribute to limitations and restrictions to participation in daily life in people with rheumatic diseases and suggests roles for hand therapists beyond the immediate hand impairments. METHODS The impact of selected rheumatic diseases on functional and work disability are reviewed along with strategies for symptom management and self-management. Upper extremity impairments of selected rheumatic diseases are also discussed. RESULTS The role for hand therapists in evaluating and addressing the complex needs of persons with rheumatic diseases, including less common diseases, is discussed. Outcome measures for fatigue, muscle involvement, ergonomics and computer use, and work disability are introduced. Finally, strategies for self-management and prevention of work and functional disability, along with symptom management for fatigue and pain are presented. CONCLUSION Hand therapists can play a vital role in chronic rheumatic disease management to improve self-management and increase participation in meaningful activities. Patients, primary care and rheumatology providers need to be educated about the scope of services occupational and physical therapists provide beyond the hand impairments.
Collapse
Affiliation(s)
- Janet L Poole
- Occupational Therapy Graduate Program, University of New Mexico, Albuquerque, NM, USA.
| |
Collapse
|
13
|
Karadag O, Dalkilic E, Ayan G, Kucuksahin O, Kasifoglu T, Yilmaz N, Koca SS, Yazisiz V, Erten PT, Sayarlioglu M, Terzioglu ME, Erten S, Kalyoncu U. Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study. Clin Rheumatol 2021; 41:85-94. [PMID: 34477993 DOI: 10.1007/s10067-021-05893-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Revised: 07/29/2021] [Accepted: 08/23/2021] [Indexed: 01/01/2023]
Abstract
OBJECTIVES To understand change in work productivity, activity impairment, quality of life (QoL), and disease activity in patients with psoriatic arthritis (PsA) receiving anti-tumor necrosis factor (anti-TNF) treatment. METHOD One hundred twenty patients with PsA receiving anti-TNF therapy were recruited to this noninterventional, observational study. Work disability was assessed via the Work Productivity and Activity Impairment (WPAI) questionnaire and disease activity was calculated via the 28-joint Disease Activity Score using C-reactive protein (DAS28-CRP) and Disease Activity Index for Psoriatic Arthritis with 28 joints (DAPSA28) score. Patient-reported outcomes (PROs), from visual analog scores and Health Assessment Questionnaire-Disability Index scores, were evaluated to understand the clinical effectiveness at baseline and every 3 months until the month-9 final visit. The American College of Rheumatology (ACR)20/50/70 response criteria were assessed at month 9. RESULTS A total of 120 patients (females, n = 73) were enrolled in the study. Mean (SD) age and disease duration were 41.6 ± 11.1 years and 6.9 ± 6.5 years, respectively. The most commonly used TNFα inhibitor was adalimumab (42.4%), followed by etanercept (25.8%). All WPAI questionnaire parameters were reduced at the follow-up visits compared with baseline (p < 0.001 for all). PROs and disease activity indicators (DAS28-CRP and DAPSA28) significantly improved during the course of anti-TNF treatments (p < 0.001 for all). Additionally, ACR20/50/70 responses were determined as 86.8%, 63.7%, and 41.8% of patients at the month-9 visit. CONCLUSIONS The real-world data in PsA patients receiving anti-TNF treatment showed improvement in WPAI, QoL, and disease activity over 9 months of treatment. TRIAL REGISTRATION NCT02028169 Key Points • Psoriatic arthritis (PsA), with debilitating effects on quality of life, occurs mostly in young adults and has negative impacts on employment status and work productivity. • Early PsA diagnosis and treat-to-target treatment strategies aim to reduce pain and joint damage, as well as improve work productivity. • Real-world data on the impact of treatment with anti-tumor necrosis factor (anti-TNF) agents on work productivity in PsA in the literature is scarce. • Our study of real-world data in patients with PsA receiving anti-TNF treatment showed improvement in work productivity, as well as in clinical and patient-reported outcomes.
Collapse
Affiliation(s)
- Omer Karadag
- School of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey.
| | - Ediz Dalkilic
- School of Medicine, Department of Internal Medicine, Division of Rheumatology, Uludag University, Bursa, Turkey
| | - Gizem Ayan
- School of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
| | - Orhan Kucuksahin
- Ankara City Hospital - School of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara Yildirim Beyazit University, Ankara, Turkey
| | - Timucin Kasifoglu
- School of Medicine, Department of Internal Medicine, Division of Rheumatology, Eskisehir Osmangazi University, Eskisehir, Turkey
| | - Neslihan Yilmaz
- Istanbul Florence Nightingale Hospital, Department of Rheumatology, Demiroglu Bilim University, Istanbul, Turkey
| | - Suleyman Serdar Koca
- School of Medicine, Department of Internal Medicine, Division of Rheumatology, Firat University, Elazig, Turkey
| | - Veli Yazisiz
- School of Medicine, Department of Internal Medicine, Division of Rheumatology, Akdeniz University, Antalya, Turkey
| | - Pinar Talu Erten
- Medical Park, Department of Internal Medicine, Division of Rheumatology, Izmir Economy University, Izmir, Turkey
| | - Mehmet Sayarlioglu
- Department of Internal Medicine, Division of Rheumatology, Liv Hospital Samsun, Samsun, Turkey
| | - Mustafa Ender Terzioglu
- School of Medicine, Department of Internal Medicine, Division of Rheumatology, Akdeniz University, Antalya, Turkey
| | - Sukran Erten
- Ankara City Hospital - School of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara Yildirim Beyazit University, Ankara, Turkey
| | - Umut Kalyoncu
- School of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
| |
Collapse
|
14
|
Boonen A, Putrik P, Marques ML, Alunno A, Abasolo L, Beaton D, Betteridge N, Bjørk M, Boers M, Boteva B, Fautrel B, Guillemin F, Mateus EF, Nikiphorou E, Péntek M, Pimentel Santos F, Severens JL, Verstappen SMM, Walker-Bone K, Wallman JK, Ter Wee MM, Westhovens R, Ramiro S. EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis. Ann Rheum Dis 2021; 80:1116-1123. [PMID: 33832966 PMCID: PMC8372378 DOI: 10.1136/annrheumdis-2020-219523] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 03/21/2021] [Accepted: 03/23/2021] [Indexed: 12/30/2022]
Abstract
BACKGROUND Clinical studies with work participation (WP) as an outcome domain pose particular methodological challenges that hamper interpretation, comparison between studies and meta-analyses. OBJECTIVES To develop Points to Consider (PtC) for design, analysis and reporting of studies of patients with inflammatory arthritis that include WP as a primary or secondary outcome domain. METHODS The EULAR Standardised Operating Procedures were followed. A multidisciplinary taskforce with 22 experts including patients with rheumatic diseases, from 10 EULAR countries and Canada, identified methodologic areas of concern. Two systematic literature reviews (SLR) appraised the methodology across these areas. In parallel, two surveys among professional societies and experts outside the taskforce sought for additional methodological areas or existing conducting/reporting recommendations. The taskforce formulated the PtC after presentation of the SLRs and survey results, and discussion. Consensus was obtained through informal voting, with levels of agreement obtained anonymously. RESULTS Two overarching principles and nine PtC were formulated. The taskforce recommends to align the work-related study objective to the design, duration, and outcome domains/measurement instruments of the study (PtC: 1-3); to identify contextual factors upfront and account for them in analyses (PtC: 4); to account for interdependence of different work outcome domains and for changes in work status over time (PtC: 5-7); to present results as means as well as proportions of patients reaching predefined meaningful categories (PtC: 8) and to explicitly report volumes of productivity loss when costs are an outcome (PtC:9). CONCLUSION Adherence to these EULAR PtC will improve the methodological quality of studies evaluating WP.
Collapse
Affiliation(s)
- Annelies Boonen
- Division of Rheumatology, Maastricht University Medical Centre+ Internal Medicine, Maastricht, The Netherlands
- Universiteit Maastricht Care and Public Health Research Institute, Maastricht, The Netherlands
| | - Polina Putrik
- Division of Rheumatology, Maastricht University Medical Centre+ Internal Medicine, Maastricht, The Netherlands
- Universiteit Maastricht Care and Public Health Research Institute, Maastricht, The Netherlands
| | - Mary Lucy Marques
- Rheumatologist, Leiden University Medical Center, Leiden, The Netherlands
- Rheumatology, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra, Portugal
| | - Alessia Alunno
- Rheumatology Unit, University of Perugia Department of Medicine, Perugia, Italy
| | - Lydia Abasolo
- Department of Rheumatology, Instituto de Investigation Sanitaria San Carlos, Hospital Clinico Universitario San Carlos, Madrid, Spain
| | - Dorcas Beaton
- Mobility Program Clinical Research Unit, St Michael's Hospital Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
| | | | - Mathilda Bjørk
- Pain and Rehabilitation Center, and Department of Health, Medicine and Caring Sciences, Linköping University, Linkoping, Sweden
| | - Maarten Boers
- Department of Epidemiology and Data Science; Amsterdam Rheumatology and Immunology Center, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Amsterdam, The Netherlands
| | - Boryana Boteva
- Patients with Arthritis and Rheumatism (PARE) working group, European League Against Rheumatism, Zurich, Switzerland
| | - Bruno Fautrel
- PEPITES teams, Pierre Louis Institute for Epidemiology and Public Health, Inserm UMR 1136, Paris, France
- Rheumatology Dept, Pitié Salpetriere Hospital, Sorbonne University / Assistance Publique- Hôpitaux de Paris, Paris, Fance
| | - Francis Guillemin
- APEMAC, Université de Lorraine, Nancy, France
- CIC Epidémiologie Clinique, CHRU Nancy, Inserm, Université de Lorraine, Nancy, France
| | - Elsa F Mateus
- Portuguese League Against Rheumatic Diseases (LPCDR) and Comprehensive Health Research Centre (CHRC), Lisbon, Portugal
- People with Arthritis and Rheumatism (PARE), European League Against Rheumatism, Zurich, Switzerland
| | - Elena Nikiphorou
- Centre for Rheumatic Diseases, King's College of London, London, UK
- Rheumatology Department, King's College Hospital, London, UK
| | - Márta Péntek
- Health Economics Research Center, University Research and Innovation Center, Óbuda University, Budapest, Hungary
| | - Fernando Pimentel Santos
- Rheumatology Department, Centro Hospitalar de Lisboa Ocidental EPE Hospital de Egas Moniz, Lisboa, Portugal
- NOVA Medical School, Lisboa, Portugal
| | - Johannes L Severens
- Erasmus School of Health Policy & Management and iMTA, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands
| | - Suzanne M M Verstappen
- Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
- Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Manchester, UK
| | - Karen Walker-Bone
- MRC Versus Arthritis Centre for Musculoskeletal Health and Work, MRC Life course Epidemiology Unit, Southampton General Hospital, Southampton, UK
| | - Johan Karlsson Wallman
- Department of Clinical sciences, Lund University, Lund, Sweden
- Department of Rheumatology, Skåne University Hospital, Lund, Sweden
| | - Marieke M Ter Wee
- Department of Epidemiology and Data Science, Amsterdam Public Health, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- Department of Rheumatology and immunology, AI&I, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - René Westhovens
- Dept of Rheumatology, KU Leuven University Hospitals Leuven, Leuven, Belgium
- Skeletal Biology and Engineering Research Centre, KU Leuven Department of Development and Regeneration, Leuven, Belgium
| | - Sofia Ramiro
- Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
- Rheumatology, Zuyderland Medical Centre Heerlen, Heerlen, The Netherlands
| |
Collapse
|
15
|
van der Burg L, Sepriano A, Landewé R, Geuskens G, Ottenheijm R, Dinant GJ, Boonen A. Comparative construct validity of three presenteeism instruments in workers with musculoskeletal complaints: a prospective cohort study. RMD Open 2021; 6:rmdopen-2020-001281. [PMID: 32868452 PMCID: PMC7507893 DOI: 10.1136/rmdopen-2020-001281] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Revised: 07/07/2020] [Accepted: 07/29/2020] [Indexed: 11/04/2022] Open
Abstract
OBJECTIVES To compare the construct validity of three presenteeism instruments, using health and economic outcomes as external references, among working persons reporting musculoskeletal complaints. METHODS Data from the prospective Study on Transitions in Employment, Ability and Motivation were used. Presenteeism measurement comprised a global rating of work-ability, and two instruments indicating at-work productivity, and was assessed yearly over 6 years of follow-up. Longitudinal associations between measures of health and subsequent presenteeism, and between presenteeism and subsequent days of sick leave were assessed using generalised estimating equation models. The effect of groups of contextual factors (socio-demographic, lifestyle, personal and work-related factors) was investigated by assessing the change in explained variability. RESULTS In total, 4523 persons were analysed. The association between physical health and work-ability was stronger than both at-work productivity measures; 10 points increase in physical health (0-100, higher is better) was associated with 0.79 points (95% CI 0.75 to 0.84) better work-ability (0-10, higher is better) in the subsequent year. Besides, work-ability best predicted sick leave; one point higher work-ability was associated with 4 days less sick leave (95% CI -5.09 to -3.63) the subsequent year. Personal factors improved model fit for models on health and work-ability, but conflicting results were seen for both at-work productivity instruments. CONCLUSION Work-ability showed higher construct validity against health and economic outcomes as compared to at-work productivity, which shows that work-ability is different to productivity (losses). Personal factors are especially relevant when interpreting the relation between health and work-ability or self-reported quantity of work.
Collapse
Affiliation(s)
- Lennart van der Burg
- Department of Family Medicine, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands .,Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre (MUMC+) and Care and Public Health Research Institute (CAPHRI), Maastricht, The Netherlands
| | - Alexandre Sepriano
- Department of Rheumatology, Leiden University Medical Center (LUMC), Leiden, The Netherlands.,NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal
| | - Robert Landewé
- Clinical Immunology & Rheumatology, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands.,Department of Rheumatology, Zuyderland Medical Center, Heerlen, The Netherlands
| | - Goedele Geuskens
- TNO, Netherlands Organization for Applied Scientific Research, Leiden, The Netherlands
| | - Ramon Ottenheijm
- Department of Family Medicine, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands
| | - Geert-Jan Dinant
- Department of Family Medicine, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands
| | - Annelies Boonen
- Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre (MUMC+) and Care and Public Health Research Institute (CAPHRI), Maastricht, The Netherlands
| |
Collapse
|
16
|
Marques ML, Alunno A, Boonen A, Ter Wee MM, Falzon L, Ramiro S, Putrik P. Methodological aspects of design, analysis and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis: results of two systematic literature reviews informing EULAR points to consider. RMD Open 2021; 7:rmdopen-2020-001522. [PMID: 33542048 PMCID: PMC7868290 DOI: 10.1136/rmdopen-2020-001522] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 01/06/2021] [Accepted: 01/14/2021] [Indexed: 12/12/2022] Open
Abstract
Objective To summarise the methodological aspects in studies with work participation (WP) as outcome domain in inflammatory arthritis (IA) and other chronic diseases. Methods Two systematic literature reviews (SLRs) were conducted in key electronic databases (2014–2019): search 1 focused on longitudinal prospective studies in IA and search 2 on SLRs in other chronic diseases. Two reviewers independently identified eligible studies and extracted data covering pre-defined methodological areas. Results In total, 58 studies in IA (22 randomised controlled trials, 36 longitudinal observational studies) and 24 SLRs in other chronic diseases were included. WP was the primary outcome in 26/58 (45%) studies. The methodological aspects least accounted for in IA studies were as follows (proportions of studies positively adhering to the topic are shown): aligning the studied population (16/58 (28%)) and sample size calculation (8/58 (14%)) with the work-related study objective; attribution of WP to overall health (28/58 (48%)); accounting for skewness of presenteeism/sick leave (10/52 (19%)); accounting for work-related contextual factors (25/58 (43%)); reporting attrition and its reasons (1/58 (2%)); reporting both aggregated results and proportions of individuals reaching predefined meaningful change or state (11/58 (16%)). SLRs in other chronic diseases confirmed heterogeneity and methodological flaws identified in IA studies without identifying new issues. Conclusion High methodological heterogeneity was observed in studies with WP as outcome domain. Consensus around various methodological aspects specific to WP studies is needed to improve quality of future studies. This review informs the EULAR Points to Consider for conducting and reporting studies with WP as an outcome in IA.
Collapse
Affiliation(s)
- Mary Lucy Marques
- Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands .,Rheumatology, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra, Portugal
| | - Alessia Alunno
- Rheumatology Unit, University of Perugia Department of Medicine, Perugia, Umbria, Italy
| | - Annelies Boonen
- Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, Limburg, The Netherlands.,Department of Health Services Research, Universiteit Maastricht Care and Public Health Research Institute, Maastricht, Limburg, The Netherlands
| | - Marieke M Ter Wee
- Department of Epidemiology and Data Science, Amsterdam Public Health, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.,Department of Rheumatology and immunology, AI&I, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Louise Falzon
- Center for Personalized Health, Feinstein Institutes for Medical Research, Northwell Health, New York, New York, USA
| | - Sofia Ramiro
- Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands.,Rheumatology, Zuyderland Medical Centre Heerlen, Heerlen, Limburg, The Netherlands
| | - Polina Putrik
- Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, Limburg, The Netherlands.,Department of Health Services Research, Universiteit Maastricht Care and Public Health Research Institute, Maastricht, Limburg, The Netherlands
| |
Collapse
|
17
|
Fautrel B, Boonen A, de Wit M, Grimm S, Joore M, Guillemin F. Cost assessment of health interventions and diseases. RMD Open 2021; 6:rmdopen-2020-001287. [PMID: 33148784 PMCID: PMC7856133 DOI: 10.1136/rmdopen-2020-001287] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Revised: 06/08/2020] [Accepted: 06/12/2020] [Indexed: 01/24/2023] Open
Abstract
Health resource use and identification of related costs are two essential steps in health economics assessment. The elicited costs will be balanced with health outcome improvement and enable the comparison of different diagnostic procedures or therapeutic strategies from a health economic point of view. The cost typology can be disentangled in three main components, that is, direct cost related to health resource use, indirect costs related to productivity loss and sometimes intangible costs (costs related to pain and suffering). These costs can be elicited from different perspectives depending on the general aim of the assessment: payer, societal perspective or patient perspective. Practically, the first step corresponds to the quantification of health resource use, that is, number of consultations, biological or imaging workups, hospitalisation, dispensed medication units or days on sick leave. It can be done by specific self-questionnaires or by access to insurance health databases. The second step is then to value each health resource use item, based on available public databases—either produced by insurance entities or statistics institute—providing the unit costs for each item. Importantly, substantial variability does exist in the costing exercise, requiring accepting a certain uncertainty around cost estimates. This can be taken into account by sensitivity analyses, which capture in what extent measurement error can impact cost assessment, depending on different hypotheses or assumptions. One essential element of health economic assessment is the identification of costs incurred by or associated with a specific health condition for a study on the economic burden of a disease—cost-of-illness study—or with a given diagnostic or therapeutic intervention in the context of health technology assessment in which these costs are compared with the alternative reference strategy—cost-effectiveness study.
Collapse
Affiliation(s)
- Bruno Fautrel
- Sorbonne Université - Assistance Publique Hôpitaux de Paris, Pitie Salpetriere University Hospital, Rheumatology Department, Paris, France .,Institut Pierre Louis d'Epidémiologie et Santé publique, INSERM UMR S1136, Team PEPITES, Paris, France
| | - Annelies Boonen
- Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, and the CAPHRI Research Institute Maastricht University, Maastricht, Netherlands
| | - Maarten de Wit
- Patient Research Partner, EULAR, Zaltbommel, Netherlands
| | - Sabine Grimm
- Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University Medical Centre, Maastricht, The Netherlands
| | - Manuela Joore
- Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University Medical Centre, Maastricht, The Netherlands
| | | |
Collapse
|
18
|
Abstract
Objectives To identify whether it is feasible to develop a mapping algorithm to predict presenteeism using multiattribute measures of health status. Methods Data were collected using a bespoke online survey in a purposive sample (n = 472) of working individuals with a self-reported diagnosis of Rheumatoid arthritis (RA). Survey respondents were recruited using an online panel company (ResearchNow). This study used data captured using two multiattribute measures of health status (EQ5D-5 level; SF6D) and a measure of presenteeism (WPAI, Work Productivity Activity Index). Statistical correlation between the WPAI and the two measures of health status (EQ5D-5 level; SF6D) was assessed using Spearman’s rank correlation. Five regression models were estimated to quantify the relationship between WPAI and predict presenteeism using health status. The models were specified based in index and domain scores and included covariates (age; gender). Estimated and observed presenteeism were compared using tenfold cross-validation and evaluated using Root mean square error (RMSE). Results A strong and negative correlation was found between WPAI and: EQ5D-5 level and WPAI (r = − 0.64); SF6D (r =− 0.60). Two models, using ordinary least squares regression were identified as the best performing models specifying health status using: SF6D domains with age interacted with gender (RMSE = 1.7858); EQ5D-5 Level domains and age interacted with gender (RMSE = 1.7859). Conclusions This study provides indicative evidence that two existing measures of health status (SF6D and EQ5D-5L) have a quantifiable relationship with a measure of presenteeism (WPAI) for an exemplar application of working individuals with RA. A future study should assess the external validity of the proposed mapping algorithms. Supplementary Information The online version contains supplementary material available at 10.1007/s11136-021-02936-9.
Collapse
|
19
|
Karacayli U, Adesanya A, Aksoy A, Belem JMFM, Cardin NB, Sarı FB, Beyhan TE, Çelik Z, Karacayli C, Alibaz-Öner F, Inanç N, Ergun T, Yay M, Madanat W, Silva de Souza AW, Fortune F, Direskeneli H, Mumcu G. The Assessment of Presenteeism and Activity Impairment in Behcet's Syndrome and Recurrent Aphthous Stomatitis: A multicentre Study. Rheumatology (Oxford) 2021; 61:1538-1547. [PMID: 34289015 DOI: 10.1093/rheumatology/keab581] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Revised: 07/06/2021] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVE To evaluate key factors for Presenteeism and Activity impairment in multinational patients with Behçet's syndrome (BS) and recurrent aphthous stomatitis (RAS). METHODS In this cross-sectional study, 364 BS patients from Jordan, Brazil, the United Kingdom and Turkey and 143 RAS patients from the United Kingdom and Turkey were included. Work Productivity Activity Impairment (WPAI) scale was used for Presenteeism and Activity impairment. Mediation analyses were performed to evaluate both direct and indirect causal effects. RESULTS Presenteeism score was higher in active patients with genital ulcers and eye involvement as well as patients with comorbidities and current smokers than the others in BS (p< 0.05). In RAS, Presenteeism score was elevated by oral ulcer activity in the direct path (p= 0.0073) and long disease duration as a mediator in the indirect path (p= 0.0191).Patients with active joint involvement had poor scores in Absenteeism, Presenteeism, Overall impairment and Activity impairment compared with those of inactive patients (p < 0.05). Using mediation analysis, the Activity impairment score was directly mediated by joint activity (p = 0.0001) and indirectly mediated through oral ulcer-related pain in BS (p = 0.0309). CONCLUSION In BS, Presenteeism was associated with disease activity, presence of comorbidities and being a current smoker, whereas in RAS, Presenteeism was associated with oral ulcer activity and increased length of the disease. Moreover, Activity impairment was adversely affected by joint activity and oral ulcer related pain in BS. Patients need to be empowered by using appropriate treatment strategies in their working environment and daily life.
Collapse
Affiliation(s)
- Umit Karacayli
- Department of Oral and Maxillofacial Surgery, Gulhane Faculty of Dentistry, University of Health Sciences, Ankara, Turkey
| | - Adebowale Adesanya
- Barts and The London School of Medicine and Dentistry, Centre Immunobiology and Regenerative Medicine, Queen Mary University of London, UK
| | - Aysun Aksoy
- Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey
| | - Joice M F M Belem
- Division of Rheumatology, Universidade Federal de São Paulo, São Paulo, Brazil
| | | | - Fatma Busra Sarı
- Department of Health Management, Faculty of Health Sciences, Marmara University, Istanbul, Turkey
| | - Tuğba Emine Beyhan
- Department of Health Management, Faculty of Health Sciences, Marmara University, Istanbul, Turkey
| | - Zülal Çelik
- Department of Health Management, Faculty of Health Sciences, Marmara University, Istanbul, Turkey
| | - Ceren Karacayli
- Department of Audiology, Gulhane Faculty of Health Science, University of Health Sciences, Ankara, Turkey.,Department of Otorhinolaryngology, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey
| | - Fatma Alibaz-Öner
- Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey
| | - Nevsun Inanç
- Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey
| | - Tülin Ergun
- Department of Dermatology, Medical School, Marmara University, Istanbul, Turkey
| | - Meral Yay
- Department of Statistics, Mimar Sinan Fine Art Faculty, Istanbul, Turkey
| | - Wafa Madanat
- Jordan's Friends of Behçet's Disease Patients Society, Medical Department, Amman, Jordan
| | | | - Farida Fortune
- Barts and The London School of Medicine and Dentistry, Centre Immunobiology and Regenerative Medicine, Queen Mary University of London, UK
| | - Haner Direskeneli
- Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey
| | - Gonca Mumcu
- Department of Health Management, Faculty of Health Sciences, Marmara University, Istanbul, Turkey
| |
Collapse
|
20
|
Reneman MF, Beemster TT, Welling SJ, Mierau JO, Dijk HH. Vocational Rehabilitation for Patients with Chronic Musculoskeletal Pain With or Without a Work Module: An Economic Evaluation. JOURNAL OF OCCUPATIONAL REHABILITATION 2021; 31:84-91. [PMID: 32816203 PMCID: PMC7954755 DOI: 10.1007/s10926-020-09921-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Purpose Vocational rehabilitation (VR) is a widely used intervention aimed to optimize work participation for patients on sick leave due to chronic musculoskeletal pain (CMP). Economic evaluations of care as usual VR are scarce, and may provide relevant information to guide clinical, reimbursement and policy decisions. The aim of this study was to evaluate the short-term cost-effectiveness and return on investment (ROI) of VR for patients on sick leave due to CMP with an additional work module (VR+) compared to VR without work module, from a societal and employers' perspective. Methods A retrospective longitudinal cohort study within a Dutch care as usual context was applied. Participants with CMP and decreased work participation originating from seven Dutch rehabilitation centers were included in this study. Participants underwent VR or VR+. Main data sources at baseline and discharge: Quality-adjusted life year (QALY) based on EQ-5D, intervention costs, self-reported productivity and health care utilization. Main analyses cost-effectiveness, including incremental cost-effectiveness ratio (ICER) and a cost-effectiveness acceptability curve (CEAC); and ROI analyses with use of the human capital method. Results N = 324 participants were analyzed. The results show that VR+ was cost-effective compared to VR: mean cost savings of €820 per 0.012 QALY gained. CEAC suggests probability of VR+ being cost-effective is > 0.91 for thresholds of €20.000 and higher. The mean ROI of VR+ for employers was 38%. Conclusion It was concluded that at discharge, VR+ was cost-effective compared to VR. ROI was positive for employers.
Collapse
Affiliation(s)
- Michiel F Reneman
- Department of Rehabilitation Medicine, Center for Rehabilitation, University Medical Center Groningen, University of Groningen, Haren, P.O. Box 30.002, 9750 RA, Groningen, The Netherlands.
| | - Timo T Beemster
- Department of Research and Development, Heliomare Rehabilitation Center, Wijk aan Zee, The Netherlands
- Department Coronel Institute of Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Sybren J Welling
- Faculty of Economics and Business, University of Groningen, Groningen, The Netherlands
| | - Jochen O Mierau
- Faculty of Economics and Business, University of Groningen, Groningen, The Netherlands
- Aletta Jacobs School of Public Health, University of Groningen, Groningen, The Netherlands
| | - Hermien H Dijk
- Faculty of Economics and Business, University of Groningen, Groningen, The Netherlands
| |
Collapse
|
21
|
Gwinnutt JM, Leggett S, Lunt M, Barton A, Hyrich KL, Walker-Bone K, Verstappen SMM. Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis. Rheumatology (Oxford) 2021; 59:2908-2919. [PMID: 32097471 PMCID: PMC7516097 DOI: 10.1093/rheumatology/keaa027] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Revised: 01/02/2020] [Indexed: 12/20/2022] Open
Abstract
Objectives Work is an important health outcome. This study aimed to identify predictors of work loss, absenteeism and presenteeism over 1 year in RA patients commencing treatment with MTX or biologics. Methods Patients aged 18–65 years in full/part-time employment from two UK prospective cohorts were included: MTX-starters = Rheumatoid Arthritis Medication Study; and biologic-starters = Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate. Presenteeism and absenteeism were assessed using the RA-specific Work Productivity Survey at baseline, and 6 and 12 months. Potential predictors including baseline age, gender, clinical measures (e.g. disability, pain, fatigue), psychological distress, occupation and EULAR response from baseline to 6 months were investigated. Results A total of 51/463 MTX-starters and 30/260 biologic-starters left work over 12 months. Higher baseline psychological distress in MTX-starters [odds ratio (OR) 1.1 (95% CI: 1.0, 1.1)] and higher disability in biologic-starters [OR 3.5 (95% CI: 1.4, 8.6)] predicted work loss. Some 16.1% of patients reported sick-leave, which was predicted by disability [OR (95% CI): MTX-starters: 1.5 (0.9, 2.3); biologic-starters: 2.4 (1.1, 5.2)]. Median presenteeism scores were very low (minimal interference) in both cohorts. Higher fatigue for MTX starters [incidence rate ratio 1.2 (95% CI: 1.0, 1.4)] and higher disability in biologic-starters (incidence rate ratio 1.4 (95% CI: 1.1, 1.7)] predicted presenteeism. Good EULAR response was associated with lower absenteeism and presenteeism in both cohorts. Conclusion Patients with RA still face significant limitations regarding their ability to work. Disability and EULAR response were the main predictors of work outcomes, emphasizing the need to control the disease and the importance of function in enabling work participation.
Collapse
Affiliation(s)
- James M Gwinnutt
- Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester
| | - Sarah Leggett
- Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester
| | - Mark Lunt
- Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester
| | - Anne Barton
- Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester.,NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester
| | - Kimme L Hyrich
- Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester.,NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester
| | - Karen Walker-Bone
- MRC Versus Arthritis Centre for Musculoskeletal Health and Work, University of Southampton, Southampton, UK
| | - Suzanne M M Verstappen
- Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester.,NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester.,MRC Versus Arthritis Centre for Musculoskeletal Health and Work, University of Southampton, Southampton, UK
| | | |
Collapse
|
22
|
Ortiz-Haro AB, Lerma-Talamantes A, Cabrera-Vanegas Á, Contreras-Yáñez I, Pascual-Ramos V. Development and validation of a questionnaire assessing household work limitations (HOWL-Q) in women with rheumatoid arthritis. PLoS One 2020; 15:e0236167. [PMID: 32701988 PMCID: PMC7377421 DOI: 10.1371/journal.pone.0236167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Accepted: 06/30/2020] [Indexed: 11/23/2022] Open
Abstract
INTRODUCTION Rheumatoid arthritis (RA) has female preponderance and interferes with the ability to perform job roles. Household work has 2 dimensions, paid and unpaid. There is not a validated instrument that assesses the impact of RA on limitations to perform household work. We report the development and validation of a questionnaire that assesses such limitations, the HOWL-Q. METHODS The study was performed in 3 steps. Step-1 consisted on HOWL-Q conceptual model construction (literature review and semi-structured interviews to 20 RA outpatients and 20 controls, household workers, who integrated sample (S)-1). Step-2 consisted of instructions selection (by 25 outpatients integrating S-2), items generation and reduction (theory and key informant suggestions, modified natural semantic network technique, and pilot testing in 200 household workers outpatients conforming S-3), items scoring, and questionnaire feasibility (in S-3). Step-3 consisted of construct (exploratory factor analysis) and criterion validity (Spearman correlations), and HOWL-Q reliability (McDonald's Omega and test-retest), in 230 household work outpatients integrating S-4. RESULTS Patients conforming the 4 samples were representative of typical RA outpatients. The initial conceptual model included 8 dimensions and 76 tasks/activities. The final version included 41 items distributed in 5 dimensions, was found feasible and resulted in 62.46% of the variance explained: McDonald's Omega = 0.959, intraclass-correlation-coefficient = 0.921 (95% CI = 0.851-0.957). Moderate-to-high correlations were found between the HOLW-Q, the HAQ, the Quick-DASH and the Lawton-Brody index. HOWL-Q score ranged from 0 to 10, with increasing scores translate into increase limitations. CONCLUSION The HOWL-Q showed adequate psychometric properties to evaluate household work limitations in women with RA.
Collapse
Affiliation(s)
- Ana Belén Ortiz-Haro
- Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - Abel Lerma-Talamantes
- Health Sciences Institute, Psychology Academic Area, Universidad Autónoma del Estado de Hidalgo, Pachuca, Mexico
| | - Ángel Cabrera-Vanegas
- Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - Irazú Contreras-Yáñez
- Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - Virginia Pascual-Ramos
- Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| |
Collapse
|
23
|
Xiang L, Low AHL, Leung YY, Fong W, Gan WH, Graves N, Thumboo J. Work disability in rheumatic diseases: Baseline results from an inception cohort. Int J Rheum Dis 2020; 23:1040-1049. [PMID: 32512639 DOI: 10.1111/1756-185x.13864] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2020] [Revised: 04/30/2020] [Accepted: 05/06/2020] [Indexed: 12/18/2022]
Abstract
AIM We aimed to characterize work disability in patients with newly diagnosed rheumatic diseases and compare work characteristics between patients with rheumatic diseases and controls without rheumatic diseases at diagnosis. METHODS Patients with inflammatory arthritis (IA) and osteoarthritis (OA), surrogates for autoimmune and non-autoimmune rheumatic diseases, respectively, and controls of working age were surveyed at diagnosis. Patients with rheumatic diseases who were employed before symptom onset were characterized as having work disability if they reported reduced work ability and productivity while remaining in the same job as before symptom onset, changed to a less demanding job or stopped working/retired. Work characteristics at diagnosis were compared between rheumatic diseases patients and controls. RESULTS The unemployment rate before symptom onset was lower in patients with IA (20%) compared to patients with OA (32%). Among patients with IA and OA who were employed before symptom onset, 59% and 43% reported work disability, respectively (P = .04). The unemployment rate at diagnosis was comparable in patients with IA (26%) and higher in patients with OA (38%) compared to controls (29%). Employed patients with IA and OA, when compared with controls, reported poorer work ability (score: 37 vs 39 vs 41, P < .01; proportion with poor/moderate work ability: 48% vs 33% vs 21%, P < .01) and greater work productivity loss (score: 32 vs 29 vs 17, P < .01) at diagnosis. CONCLUSION Rheumatic diseases impose significant work disability at diagnosis, highlighting the need for identification and interventions targeting work disability early in the course of disease.
Collapse
Affiliation(s)
- Ling Xiang
- Department of Rheumatology and Immunology, Singapore General Hospital, Singapore City, Singapore
| | - Andrea H L Low
- Department of Rheumatology and Immunology, Singapore General Hospital, Singapore City, Singapore.,Duke-NUS Medical School, Singapore City, Singapore.,Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore
| | - Ying Ying Leung
- Department of Rheumatology and Immunology, Singapore General Hospital, Singapore City, Singapore.,Duke-NUS Medical School, Singapore City, Singapore.,Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore
| | - Warren Fong
- Department of Rheumatology and Immunology, Singapore General Hospital, Singapore City, Singapore.,Duke-NUS Medical School, Singapore City, Singapore.,Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore
| | - Wee Hoe Gan
- Department of Occupational and Environmental Medicine, Singapore General Hospital, Singapore City, Singapore
| | - Nicholas Graves
- Health Services and Systems Research, Duke-NUS Medical School, Singapore City, Singapore
| | - Julian Thumboo
- Department of Rheumatology and Immunology, Singapore General Hospital, Singapore City, Singapore.,Duke-NUS Medical School, Singapore City, Singapore.,Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore
| |
Collapse
|
24
|
Wilkie R, Bjork M, Costa-Black KM, Parker M, Pransky G. Managing work participation for people with rheumatic and musculoskeletal diseases. Best Pract Res Clin Rheumatol 2020; 34:101517. [PMID: 32321677 DOI: 10.1016/j.berh.2020.101517] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Improving work participation for individuals with rheumatic and musculoskeletal diseases (RMDs), has gained increasing interest over the last 10 years. New approaches are based upon increasing adoption of a biopsychosocial approach to improving work participation, incorporating evidence that health professionals within multidisciplinary teams have a key and critical role. In particular, interaction between health professionals and employers, and rehabilitation services that are linked to the workplace are key elements for improving work participation for people with RMDs. This review outlines recent research that underpins approaches for health professionals to develop their role in improving work participation for people with RMDs based on recent research; it outlines how to measure work-related outcomes in clinical practice, models of work participation, and approaches for health professionals to improve work participation outcomes. The potential for developing the role of health professionals in future years is also outlined.
Collapse
Affiliation(s)
- Ross Wilkie
- Versus Arthritis Primary Care Centre, School of Primary, Community and Social Care, Keele University, Keele, Staffordshire, ST5 5BG, United Kingdom; MRC Versus Arthritis Centre for Musculoskeletal Health and Work, University of Southampton, UK.
| | - Mathilda Bjork
- Unit of Occupational Therapy, Department of Health, Medicine and Caring Sciences, Faculty of Health Sciences, Linköping University, Department of Rheumatology, Heart and Medicine Center, Region Östergötland, Sweden.
| | - Katia M Costa-Black
- The British Standards Institution, Environmental Health and Safety Services and Solutions, Hillsboro, OR, USA; Graduate Program in Ergonomics and Biomechanics, School of Medicine, New York University, New York, NY, USA.
| | - Marty Parker
- Versus Arthritis Primary Care Centre, School of Primary, Community and Social Care, Keele University, Keele, Staffordshire, ST5 5BG, United Kingdom.
| | - Glenn Pransky
- Dept. of Quantitative Health Sciences, Univ of Massachusetts Medical School, Worcester, MA, USA.
| |
Collapse
|
25
|
Verstappen SMM, Lacaille D, Boonen A, Escorpizo R, Hofstetter C, Bosworth A, Leong A, Leggett S, Gignac MAM, Wallman JK, Ter Wee MM, Berghea F, Agaliotis M, Tugwell P, Beaton D. Considerations for Evaluating and Recommending Worker Productivity Outcome Measures: An Update from the OMERACT Worker Productivity Group. J Rheumatol 2019; 46:1401-1405. [PMID: 30936275 DOI: 10.3899/jrheum.181201] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/22/2019] [Indexed: 01/14/2023]
Abstract
OBJECTIVE The Outcome Measures in Rheumatology (OMERACT) Worker Productivity Group continues efforts to assess psychometric properties of measures of presenteeism. METHODS Psychometric properties of single-item and dual answer multiitem scales were assessed, as well as methods to evaluate thresholds of meaning. RESULTS Test-retest reliability and construct validity of single item global measures was moderate to good. The value of measuring both degree of difficulty and amount of time with difficulty in multiitems questionnaires was confirmed. Thresholds of meaning vary depending on methods and external anchors applied. CONCLUSION We have advanced our understanding of the performance of presenteeism measures and have developed approaches to describing thresholds of meaning.
Collapse
Affiliation(s)
- Suzanne M M Verstappen
- From the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; UK National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester Academic Health Science Centre, Manchester; Arthritis Research UK/Medical Research Council (MRC) Centre for Musculoskeletal Health and Work, University of Southampton, Southampton; National Rheumatoid Arthritis Society (NRAS), Maidenhead, UK; Department of Medicine, and the Division of Rheumatology, University of British Columbia, Vancouver; Arthritis Research Canada, Richmond, British Columbia; Institute for Work & Health; University of Toronto, Toronto; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Division of Rheumatology, Maastricht University Medical Center, Care and Public Health Research Institute (CAPHRI), Maastricht; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands; Department of Rehabilitation and Movement Science, University of Vermont, Burlington, Vermont, USA; Swiss Paraplegic Research, Nottwil, Switzerland; Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Carol Davila University of Medicine, Bucharest, Romania; School of Public Health and Community Medicine, University of New South Wales, Kensington, Australia. .,S.M. Verstappen, PhD, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, and Arthritis Research UK/MRC Centre for Musculoskeletal Health and Work, University of Southampton; D. Lacaille, MDCM, FRCPC, MHSc, Department of Medicine, and the Division of Rheumatology, Department of Medicine, University of British Columbia, and Arthritis Research Canada; A. Boonen, MD, PhD, Division of Rheumatology, Maastricht University Medical Center, CAPHRI; R. Escorpizo, BSc, MSc, DPT, Department of Rehabilitation and Movement Science, University of Vermont, and Swiss Paraplegic Research; C. Hofstetter, OMERACT Patient Research Partner; A. Bosworth, MBE, OMERACT Patient Research Partner, NRAS; A. Leong, OMERACT Patient Research Partner; S. Leggett, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; M.A. Gignac, PhD, Institute for Work & Health, and University of Toronto; J.K. Wallman, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology; M.M. Ter Wee, PhD, MSc, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, and Department of Rheumatology, Amsterdam Infection and Immunity Institute, Amsterdam Public Health; F. Berghea, MD, PhD, Carol Davila University of Medicine; M. Agaliotis, PhD, MSc, Australian Institute of Health Management Services, University of Tasmania; P. Tugwell, MD, MSc, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute; D. Beaton, PhD, Institute for Work & Health, and University of Toronto.
| | - Diane Lacaille
- From the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; UK National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester Academic Health Science Centre, Manchester; Arthritis Research UK/Medical Research Council (MRC) Centre for Musculoskeletal Health and Work, University of Southampton, Southampton; National Rheumatoid Arthritis Society (NRAS), Maidenhead, UK; Department of Medicine, and the Division of Rheumatology, University of British Columbia, Vancouver; Arthritis Research Canada, Richmond, British Columbia; Institute for Work & Health; University of Toronto, Toronto; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Division of Rheumatology, Maastricht University Medical Center, Care and Public Health Research Institute (CAPHRI), Maastricht; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands; Department of Rehabilitation and Movement Science, University of Vermont, Burlington, Vermont, USA; Swiss Paraplegic Research, Nottwil, Switzerland; Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Carol Davila University of Medicine, Bucharest, Romania; School of Public Health and Community Medicine, University of New South Wales, Kensington, Australia.,S.M. Verstappen, PhD, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, and Arthritis Research UK/MRC Centre for Musculoskeletal Health and Work, University of Southampton; D. Lacaille, MDCM, FRCPC, MHSc, Department of Medicine, and the Division of Rheumatology, Department of Medicine, University of British Columbia, and Arthritis Research Canada; A. Boonen, MD, PhD, Division of Rheumatology, Maastricht University Medical Center, CAPHRI; R. Escorpizo, BSc, MSc, DPT, Department of Rehabilitation and Movement Science, University of Vermont, and Swiss Paraplegic Research; C. Hofstetter, OMERACT Patient Research Partner; A. Bosworth, MBE, OMERACT Patient Research Partner, NRAS; A. Leong, OMERACT Patient Research Partner; S. Leggett, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; M.A. Gignac, PhD, Institute for Work & Health, and University of Toronto; J.K. Wallman, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology; M.M. Ter Wee, PhD, MSc, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, and Department of Rheumatology, Amsterdam Infection and Immunity Institute, Amsterdam Public Health; F. Berghea, MD, PhD, Carol Davila University of Medicine; M. Agaliotis, PhD, MSc, Australian Institute of Health Management Services, University of Tasmania; P. Tugwell, MD, MSc, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute; D. Beaton, PhD, Institute for Work & Health, and University of Toronto
| | - Annelies Boonen
- From the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; UK National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester Academic Health Science Centre, Manchester; Arthritis Research UK/Medical Research Council (MRC) Centre for Musculoskeletal Health and Work, University of Southampton, Southampton; National Rheumatoid Arthritis Society (NRAS), Maidenhead, UK; Department of Medicine, and the Division of Rheumatology, University of British Columbia, Vancouver; Arthritis Research Canada, Richmond, British Columbia; Institute for Work & Health; University of Toronto, Toronto; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Division of Rheumatology, Maastricht University Medical Center, Care and Public Health Research Institute (CAPHRI), Maastricht; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands; Department of Rehabilitation and Movement Science, University of Vermont, Burlington, Vermont, USA; Swiss Paraplegic Research, Nottwil, Switzerland; Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Carol Davila University of Medicine, Bucharest, Romania; School of Public Health and Community Medicine, University of New South Wales, Kensington, Australia.,S.M. Verstappen, PhD, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, and Arthritis Research UK/MRC Centre for Musculoskeletal Health and Work, University of Southampton; D. Lacaille, MDCM, FRCPC, MHSc, Department of Medicine, and the Division of Rheumatology, Department of Medicine, University of British Columbia, and Arthritis Research Canada; A. Boonen, MD, PhD, Division of Rheumatology, Maastricht University Medical Center, CAPHRI; R. Escorpizo, BSc, MSc, DPT, Department of Rehabilitation and Movement Science, University of Vermont, and Swiss Paraplegic Research; C. Hofstetter, OMERACT Patient Research Partner; A. Bosworth, MBE, OMERACT Patient Research Partner, NRAS; A. Leong, OMERACT Patient Research Partner; S. Leggett, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; M.A. Gignac, PhD, Institute for Work & Health, and University of Toronto; J.K. Wallman, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology; M.M. Ter Wee, PhD, MSc, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, and Department of Rheumatology, Amsterdam Infection and Immunity Institute, Amsterdam Public Health; F. Berghea, MD, PhD, Carol Davila University of Medicine; M. Agaliotis, PhD, MSc, Australian Institute of Health Management Services, University of Tasmania; P. Tugwell, MD, MSc, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute; D. Beaton, PhD, Institute for Work & Health, and University of Toronto
| | - Reuben Escorpizo
- From the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; UK National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester Academic Health Science Centre, Manchester; Arthritis Research UK/Medical Research Council (MRC) Centre for Musculoskeletal Health and Work, University of Southampton, Southampton; National Rheumatoid Arthritis Society (NRAS), Maidenhead, UK; Department of Medicine, and the Division of Rheumatology, University of British Columbia, Vancouver; Arthritis Research Canada, Richmond, British Columbia; Institute for Work & Health; University of Toronto, Toronto; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Division of Rheumatology, Maastricht University Medical Center, Care and Public Health Research Institute (CAPHRI), Maastricht; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands; Department of Rehabilitation and Movement Science, University of Vermont, Burlington, Vermont, USA; Swiss Paraplegic Research, Nottwil, Switzerland; Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Carol Davila University of Medicine, Bucharest, Romania; School of Public Health and Community Medicine, University of New South Wales, Kensington, Australia.,S.M. Verstappen, PhD, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, and Arthritis Research UK/MRC Centre for Musculoskeletal Health and Work, University of Southampton; D. Lacaille, MDCM, FRCPC, MHSc, Department of Medicine, and the Division of Rheumatology, Department of Medicine, University of British Columbia, and Arthritis Research Canada; A. Boonen, MD, PhD, Division of Rheumatology, Maastricht University Medical Center, CAPHRI; R. Escorpizo, BSc, MSc, DPT, Department of Rehabilitation and Movement Science, University of Vermont, and Swiss Paraplegic Research; C. Hofstetter, OMERACT Patient Research Partner; A. Bosworth, MBE, OMERACT Patient Research Partner, NRAS; A. Leong, OMERACT Patient Research Partner; S. Leggett, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; M.A. Gignac, PhD, Institute for Work & Health, and University of Toronto; J.K. Wallman, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology; M.M. Ter Wee, PhD, MSc, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, and Department of Rheumatology, Amsterdam Infection and Immunity Institute, Amsterdam Public Health; F. Berghea, MD, PhD, Carol Davila University of Medicine; M. Agaliotis, PhD, MSc, Australian Institute of Health Management Services, University of Tasmania; P. Tugwell, MD, MSc, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute; D. Beaton, PhD, Institute for Work & Health, and University of Toronto
| | - Catherine Hofstetter
- From the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; UK National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester Academic Health Science Centre, Manchester; Arthritis Research UK/Medical Research Council (MRC) Centre for Musculoskeletal Health and Work, University of Southampton, Southampton; National Rheumatoid Arthritis Society (NRAS), Maidenhead, UK; Department of Medicine, and the Division of Rheumatology, University of British Columbia, Vancouver; Arthritis Research Canada, Richmond, British Columbia; Institute for Work & Health; University of Toronto, Toronto; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Division of Rheumatology, Maastricht University Medical Center, Care and Public Health Research Institute (CAPHRI), Maastricht; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands; Department of Rehabilitation and Movement Science, University of Vermont, Burlington, Vermont, USA; Swiss Paraplegic Research, Nottwil, Switzerland; Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Carol Davila University of Medicine, Bucharest, Romania; School of Public Health and Community Medicine, University of New South Wales, Kensington, Australia.,S.M. Verstappen, PhD, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, and Arthritis Research UK/MRC Centre for Musculoskeletal Health and Work, University of Southampton; D. Lacaille, MDCM, FRCPC, MHSc, Department of Medicine, and the Division of Rheumatology, Department of Medicine, University of British Columbia, and Arthritis Research Canada; A. Boonen, MD, PhD, Division of Rheumatology, Maastricht University Medical Center, CAPHRI; R. Escorpizo, BSc, MSc, DPT, Department of Rehabilitation and Movement Science, University of Vermont, and Swiss Paraplegic Research; C. Hofstetter, OMERACT Patient Research Partner; A. Bosworth, MBE, OMERACT Patient Research Partner, NRAS; A. Leong, OMERACT Patient Research Partner; S. Leggett, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; M.A. Gignac, PhD, Institute for Work & Health, and University of Toronto; J.K. Wallman, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology; M.M. Ter Wee, PhD, MSc, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, and Department of Rheumatology, Amsterdam Infection and Immunity Institute, Amsterdam Public Health; F. Berghea, MD, PhD, Carol Davila University of Medicine; M. Agaliotis, PhD, MSc, Australian Institute of Health Management Services, University of Tasmania; P. Tugwell, MD, MSc, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute; D. Beaton, PhD, Institute for Work & Health, and University of Toronto
| | - Ailsa Bosworth
- From the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; UK National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester Academic Health Science Centre, Manchester; Arthritis Research UK/Medical Research Council (MRC) Centre for Musculoskeletal Health and Work, University of Southampton, Southampton; National Rheumatoid Arthritis Society (NRAS), Maidenhead, UK; Department of Medicine, and the Division of Rheumatology, University of British Columbia, Vancouver; Arthritis Research Canada, Richmond, British Columbia; Institute for Work & Health; University of Toronto, Toronto; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Division of Rheumatology, Maastricht University Medical Center, Care and Public Health Research Institute (CAPHRI), Maastricht; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands; Department of Rehabilitation and Movement Science, University of Vermont, Burlington, Vermont, USA; Swiss Paraplegic Research, Nottwil, Switzerland; Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Carol Davila University of Medicine, Bucharest, Romania; School of Public Health and Community Medicine, University of New South Wales, Kensington, Australia.,S.M. Verstappen, PhD, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, and Arthritis Research UK/MRC Centre for Musculoskeletal Health and Work, University of Southampton; D. Lacaille, MDCM, FRCPC, MHSc, Department of Medicine, and the Division of Rheumatology, Department of Medicine, University of British Columbia, and Arthritis Research Canada; A. Boonen, MD, PhD, Division of Rheumatology, Maastricht University Medical Center, CAPHRI; R. Escorpizo, BSc, MSc, DPT, Department of Rehabilitation and Movement Science, University of Vermont, and Swiss Paraplegic Research; C. Hofstetter, OMERACT Patient Research Partner; A. Bosworth, MBE, OMERACT Patient Research Partner, NRAS; A. Leong, OMERACT Patient Research Partner; S. Leggett, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; M.A. Gignac, PhD, Institute for Work & Health, and University of Toronto; J.K. Wallman, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology; M.M. Ter Wee, PhD, MSc, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, and Department of Rheumatology, Amsterdam Infection and Immunity Institute, Amsterdam Public Health; F. Berghea, MD, PhD, Carol Davila University of Medicine; M. Agaliotis, PhD, MSc, Australian Institute of Health Management Services, University of Tasmania; P. Tugwell, MD, MSc, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute; D. Beaton, PhD, Institute for Work & Health, and University of Toronto
| | - Amye Leong
- From the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; UK National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester Academic Health Science Centre, Manchester; Arthritis Research UK/Medical Research Council (MRC) Centre for Musculoskeletal Health and Work, University of Southampton, Southampton; National Rheumatoid Arthritis Society (NRAS), Maidenhead, UK; Department of Medicine, and the Division of Rheumatology, University of British Columbia, Vancouver; Arthritis Research Canada, Richmond, British Columbia; Institute for Work & Health; University of Toronto, Toronto; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Division of Rheumatology, Maastricht University Medical Center, Care and Public Health Research Institute (CAPHRI), Maastricht; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands; Department of Rehabilitation and Movement Science, University of Vermont, Burlington, Vermont, USA; Swiss Paraplegic Research, Nottwil, Switzerland; Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Carol Davila University of Medicine, Bucharest, Romania; School of Public Health and Community Medicine, University of New South Wales, Kensington, Australia.,S.M. Verstappen, PhD, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, and Arthritis Research UK/MRC Centre for Musculoskeletal Health and Work, University of Southampton; D. Lacaille, MDCM, FRCPC, MHSc, Department of Medicine, and the Division of Rheumatology, Department of Medicine, University of British Columbia, and Arthritis Research Canada; A. Boonen, MD, PhD, Division of Rheumatology, Maastricht University Medical Center, CAPHRI; R. Escorpizo, BSc, MSc, DPT, Department of Rehabilitation and Movement Science, University of Vermont, and Swiss Paraplegic Research; C. Hofstetter, OMERACT Patient Research Partner; A. Bosworth, MBE, OMERACT Patient Research Partner, NRAS; A. Leong, OMERACT Patient Research Partner; S. Leggett, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; M.A. Gignac, PhD, Institute for Work & Health, and University of Toronto; J.K. Wallman, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology; M.M. Ter Wee, PhD, MSc, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, and Department of Rheumatology, Amsterdam Infection and Immunity Institute, Amsterdam Public Health; F. Berghea, MD, PhD, Carol Davila University of Medicine; M. Agaliotis, PhD, MSc, Australian Institute of Health Management Services, University of Tasmania; P. Tugwell, MD, MSc, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute; D. Beaton, PhD, Institute for Work & Health, and University of Toronto
| | - Sarah Leggett
- From the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; UK National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester Academic Health Science Centre, Manchester; Arthritis Research UK/Medical Research Council (MRC) Centre for Musculoskeletal Health and Work, University of Southampton, Southampton; National Rheumatoid Arthritis Society (NRAS), Maidenhead, UK; Department of Medicine, and the Division of Rheumatology, University of British Columbia, Vancouver; Arthritis Research Canada, Richmond, British Columbia; Institute for Work & Health; University of Toronto, Toronto; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Division of Rheumatology, Maastricht University Medical Center, Care and Public Health Research Institute (CAPHRI), Maastricht; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands; Department of Rehabilitation and Movement Science, University of Vermont, Burlington, Vermont, USA; Swiss Paraplegic Research, Nottwil, Switzerland; Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Carol Davila University of Medicine, Bucharest, Romania; School of Public Health and Community Medicine, University of New South Wales, Kensington, Australia.,S.M. Verstappen, PhD, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, and Arthritis Research UK/MRC Centre for Musculoskeletal Health and Work, University of Southampton; D. Lacaille, MDCM, FRCPC, MHSc, Department of Medicine, and the Division of Rheumatology, Department of Medicine, University of British Columbia, and Arthritis Research Canada; A. Boonen, MD, PhD, Division of Rheumatology, Maastricht University Medical Center, CAPHRI; R. Escorpizo, BSc, MSc, DPT, Department of Rehabilitation and Movement Science, University of Vermont, and Swiss Paraplegic Research; C. Hofstetter, OMERACT Patient Research Partner; A. Bosworth, MBE, OMERACT Patient Research Partner, NRAS; A. Leong, OMERACT Patient Research Partner; S. Leggett, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; M.A. Gignac, PhD, Institute for Work & Health, and University of Toronto; J.K. Wallman, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology; M.M. Ter Wee, PhD, MSc, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, and Department of Rheumatology, Amsterdam Infection and Immunity Institute, Amsterdam Public Health; F. Berghea, MD, PhD, Carol Davila University of Medicine; M. Agaliotis, PhD, MSc, Australian Institute of Health Management Services, University of Tasmania; P. Tugwell, MD, MSc, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute; D. Beaton, PhD, Institute for Work & Health, and University of Toronto
| | - Monique A M Gignac
- From the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; UK National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester Academic Health Science Centre, Manchester; Arthritis Research UK/Medical Research Council (MRC) Centre for Musculoskeletal Health and Work, University of Southampton, Southampton; National Rheumatoid Arthritis Society (NRAS), Maidenhead, UK; Department of Medicine, and the Division of Rheumatology, University of British Columbia, Vancouver; Arthritis Research Canada, Richmond, British Columbia; Institute for Work & Health; University of Toronto, Toronto; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Division of Rheumatology, Maastricht University Medical Center, Care and Public Health Research Institute (CAPHRI), Maastricht; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands; Department of Rehabilitation and Movement Science, University of Vermont, Burlington, Vermont, USA; Swiss Paraplegic Research, Nottwil, Switzerland; Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Carol Davila University of Medicine, Bucharest, Romania; School of Public Health and Community Medicine, University of New South Wales, Kensington, Australia.,S.M. Verstappen, PhD, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, and Arthritis Research UK/MRC Centre for Musculoskeletal Health and Work, University of Southampton; D. Lacaille, MDCM, FRCPC, MHSc, Department of Medicine, and the Division of Rheumatology, Department of Medicine, University of British Columbia, and Arthritis Research Canada; A. Boonen, MD, PhD, Division of Rheumatology, Maastricht University Medical Center, CAPHRI; R. Escorpizo, BSc, MSc, DPT, Department of Rehabilitation and Movement Science, University of Vermont, and Swiss Paraplegic Research; C. Hofstetter, OMERACT Patient Research Partner; A. Bosworth, MBE, OMERACT Patient Research Partner, NRAS; A. Leong, OMERACT Patient Research Partner; S. Leggett, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; M.A. Gignac, PhD, Institute for Work & Health, and University of Toronto; J.K. Wallman, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology; M.M. Ter Wee, PhD, MSc, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, and Department of Rheumatology, Amsterdam Infection and Immunity Institute, Amsterdam Public Health; F. Berghea, MD, PhD, Carol Davila University of Medicine; M. Agaliotis, PhD, MSc, Australian Institute of Health Management Services, University of Tasmania; P. Tugwell, MD, MSc, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute; D. Beaton, PhD, Institute for Work & Health, and University of Toronto
| | - Johan K Wallman
- From the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; UK National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester Academic Health Science Centre, Manchester; Arthritis Research UK/Medical Research Council (MRC) Centre for Musculoskeletal Health and Work, University of Southampton, Southampton; National Rheumatoid Arthritis Society (NRAS), Maidenhead, UK; Department of Medicine, and the Division of Rheumatology, University of British Columbia, Vancouver; Arthritis Research Canada, Richmond, British Columbia; Institute for Work & Health; University of Toronto, Toronto; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Division of Rheumatology, Maastricht University Medical Center, Care and Public Health Research Institute (CAPHRI), Maastricht; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands; Department of Rehabilitation and Movement Science, University of Vermont, Burlington, Vermont, USA; Swiss Paraplegic Research, Nottwil, Switzerland; Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Carol Davila University of Medicine, Bucharest, Romania; School of Public Health and Community Medicine, University of New South Wales, Kensington, Australia.,S.M. Verstappen, PhD, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, and Arthritis Research UK/MRC Centre for Musculoskeletal Health and Work, University of Southampton; D. Lacaille, MDCM, FRCPC, MHSc, Department of Medicine, and the Division of Rheumatology, Department of Medicine, University of British Columbia, and Arthritis Research Canada; A. Boonen, MD, PhD, Division of Rheumatology, Maastricht University Medical Center, CAPHRI; R. Escorpizo, BSc, MSc, DPT, Department of Rehabilitation and Movement Science, University of Vermont, and Swiss Paraplegic Research; C. Hofstetter, OMERACT Patient Research Partner; A. Bosworth, MBE, OMERACT Patient Research Partner, NRAS; A. Leong, OMERACT Patient Research Partner; S. Leggett, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; M.A. Gignac, PhD, Institute for Work & Health, and University of Toronto; J.K. Wallman, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology; M.M. Ter Wee, PhD, MSc, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, and Department of Rheumatology, Amsterdam Infection and Immunity Institute, Amsterdam Public Health; F. Berghea, MD, PhD, Carol Davila University of Medicine; M. Agaliotis, PhD, MSc, Australian Institute of Health Management Services, University of Tasmania; P. Tugwell, MD, MSc, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute; D. Beaton, PhD, Institute for Work & Health, and University of Toronto
| | - Marieke M Ter Wee
- From the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; UK National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester Academic Health Science Centre, Manchester; Arthritis Research UK/Medical Research Council (MRC) Centre for Musculoskeletal Health and Work, University of Southampton, Southampton; National Rheumatoid Arthritis Society (NRAS), Maidenhead, UK; Department of Medicine, and the Division of Rheumatology, University of British Columbia, Vancouver; Arthritis Research Canada, Richmond, British Columbia; Institute for Work & Health; University of Toronto, Toronto; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Division of Rheumatology, Maastricht University Medical Center, Care and Public Health Research Institute (CAPHRI), Maastricht; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands; Department of Rehabilitation and Movement Science, University of Vermont, Burlington, Vermont, USA; Swiss Paraplegic Research, Nottwil, Switzerland; Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Carol Davila University of Medicine, Bucharest, Romania; School of Public Health and Community Medicine, University of New South Wales, Kensington, Australia.,S.M. Verstappen, PhD, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, and Arthritis Research UK/MRC Centre for Musculoskeletal Health and Work, University of Southampton; D. Lacaille, MDCM, FRCPC, MHSc, Department of Medicine, and the Division of Rheumatology, Department of Medicine, University of British Columbia, and Arthritis Research Canada; A. Boonen, MD, PhD, Division of Rheumatology, Maastricht University Medical Center, CAPHRI; R. Escorpizo, BSc, MSc, DPT, Department of Rehabilitation and Movement Science, University of Vermont, and Swiss Paraplegic Research; C. Hofstetter, OMERACT Patient Research Partner; A. Bosworth, MBE, OMERACT Patient Research Partner, NRAS; A. Leong, OMERACT Patient Research Partner; S. Leggett, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; M.A. Gignac, PhD, Institute for Work & Health, and University of Toronto; J.K. Wallman, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology; M.M. Ter Wee, PhD, MSc, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, and Department of Rheumatology, Amsterdam Infection and Immunity Institute, Amsterdam Public Health; F. Berghea, MD, PhD, Carol Davila University of Medicine; M. Agaliotis, PhD, MSc, Australian Institute of Health Management Services, University of Tasmania; P. Tugwell, MD, MSc, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute; D. Beaton, PhD, Institute for Work & Health, and University of Toronto
| | - Florian Berghea
- From the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; UK National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester Academic Health Science Centre, Manchester; Arthritis Research UK/Medical Research Council (MRC) Centre for Musculoskeletal Health and Work, University of Southampton, Southampton; National Rheumatoid Arthritis Society (NRAS), Maidenhead, UK; Department of Medicine, and the Division of Rheumatology, University of British Columbia, Vancouver; Arthritis Research Canada, Richmond, British Columbia; Institute for Work & Health; University of Toronto, Toronto; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Division of Rheumatology, Maastricht University Medical Center, Care and Public Health Research Institute (CAPHRI), Maastricht; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands; Department of Rehabilitation and Movement Science, University of Vermont, Burlington, Vermont, USA; Swiss Paraplegic Research, Nottwil, Switzerland; Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Carol Davila University of Medicine, Bucharest, Romania; School of Public Health and Community Medicine, University of New South Wales, Kensington, Australia.,S.M. Verstappen, PhD, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, and Arthritis Research UK/MRC Centre for Musculoskeletal Health and Work, University of Southampton; D. Lacaille, MDCM, FRCPC, MHSc, Department of Medicine, and the Division of Rheumatology, Department of Medicine, University of British Columbia, and Arthritis Research Canada; A. Boonen, MD, PhD, Division of Rheumatology, Maastricht University Medical Center, CAPHRI; R. Escorpizo, BSc, MSc, DPT, Department of Rehabilitation and Movement Science, University of Vermont, and Swiss Paraplegic Research; C. Hofstetter, OMERACT Patient Research Partner; A. Bosworth, MBE, OMERACT Patient Research Partner, NRAS; A. Leong, OMERACT Patient Research Partner; S. Leggett, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; M.A. Gignac, PhD, Institute for Work & Health, and University of Toronto; J.K. Wallman, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology; M.M. Ter Wee, PhD, MSc, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, and Department of Rheumatology, Amsterdam Infection and Immunity Institute, Amsterdam Public Health; F. Berghea, MD, PhD, Carol Davila University of Medicine; M. Agaliotis, PhD, MSc, Australian Institute of Health Management Services, University of Tasmania; P. Tugwell, MD, MSc, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute; D. Beaton, PhD, Institute for Work & Health, and University of Toronto
| | - Maria Agaliotis
- From the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; UK National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester Academic Health Science Centre, Manchester; Arthritis Research UK/Medical Research Council (MRC) Centre for Musculoskeletal Health and Work, University of Southampton, Southampton; National Rheumatoid Arthritis Society (NRAS), Maidenhead, UK; Department of Medicine, and the Division of Rheumatology, University of British Columbia, Vancouver; Arthritis Research Canada, Richmond, British Columbia; Institute for Work & Health; University of Toronto, Toronto; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Division of Rheumatology, Maastricht University Medical Center, Care and Public Health Research Institute (CAPHRI), Maastricht; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands; Department of Rehabilitation and Movement Science, University of Vermont, Burlington, Vermont, USA; Swiss Paraplegic Research, Nottwil, Switzerland; Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Carol Davila University of Medicine, Bucharest, Romania; School of Public Health and Community Medicine, University of New South Wales, Kensington, Australia.,S.M. Verstappen, PhD, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, and Arthritis Research UK/MRC Centre for Musculoskeletal Health and Work, University of Southampton; D. Lacaille, MDCM, FRCPC, MHSc, Department of Medicine, and the Division of Rheumatology, Department of Medicine, University of British Columbia, and Arthritis Research Canada; A. Boonen, MD, PhD, Division of Rheumatology, Maastricht University Medical Center, CAPHRI; R. Escorpizo, BSc, MSc, DPT, Department of Rehabilitation and Movement Science, University of Vermont, and Swiss Paraplegic Research; C. Hofstetter, OMERACT Patient Research Partner; A. Bosworth, MBE, OMERACT Patient Research Partner, NRAS; A. Leong, OMERACT Patient Research Partner; S. Leggett, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; M.A. Gignac, PhD, Institute for Work & Health, and University of Toronto; J.K. Wallman, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology; M.M. Ter Wee, PhD, MSc, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, and Department of Rheumatology, Amsterdam Infection and Immunity Institute, Amsterdam Public Health; F. Berghea, MD, PhD, Carol Davila University of Medicine; M. Agaliotis, PhD, MSc, Australian Institute of Health Management Services, University of Tasmania; P. Tugwell, MD, MSc, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute; D. Beaton, PhD, Institute for Work & Health, and University of Toronto
| | - Peter Tugwell
- From the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; UK National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester Academic Health Science Centre, Manchester; Arthritis Research UK/Medical Research Council (MRC) Centre for Musculoskeletal Health and Work, University of Southampton, Southampton; National Rheumatoid Arthritis Society (NRAS), Maidenhead, UK; Department of Medicine, and the Division of Rheumatology, University of British Columbia, Vancouver; Arthritis Research Canada, Richmond, British Columbia; Institute for Work & Health; University of Toronto, Toronto; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Division of Rheumatology, Maastricht University Medical Center, Care and Public Health Research Institute (CAPHRI), Maastricht; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands; Department of Rehabilitation and Movement Science, University of Vermont, Burlington, Vermont, USA; Swiss Paraplegic Research, Nottwil, Switzerland; Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Carol Davila University of Medicine, Bucharest, Romania; School of Public Health and Community Medicine, University of New South Wales, Kensington, Australia.,S.M. Verstappen, PhD, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, and Arthritis Research UK/MRC Centre for Musculoskeletal Health and Work, University of Southampton; D. Lacaille, MDCM, FRCPC, MHSc, Department of Medicine, and the Division of Rheumatology, Department of Medicine, University of British Columbia, and Arthritis Research Canada; A. Boonen, MD, PhD, Division of Rheumatology, Maastricht University Medical Center, CAPHRI; R. Escorpizo, BSc, MSc, DPT, Department of Rehabilitation and Movement Science, University of Vermont, and Swiss Paraplegic Research; C. Hofstetter, OMERACT Patient Research Partner; A. Bosworth, MBE, OMERACT Patient Research Partner, NRAS; A. Leong, OMERACT Patient Research Partner; S. Leggett, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; M.A. Gignac, PhD, Institute for Work & Health, and University of Toronto; J.K. Wallman, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology; M.M. Ter Wee, PhD, MSc, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, and Department of Rheumatology, Amsterdam Infection and Immunity Institute, Amsterdam Public Health; F. Berghea, MD, PhD, Carol Davila University of Medicine; M. Agaliotis, PhD, MSc, Australian Institute of Health Management Services, University of Tasmania; P. Tugwell, MD, MSc, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute; D. Beaton, PhD, Institute for Work & Health, and University of Toronto
| | - Dorcas Beaton
- From the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; UK National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester Academic Health Science Centre, Manchester; Arthritis Research UK/Medical Research Council (MRC) Centre for Musculoskeletal Health and Work, University of Southampton, Southampton; National Rheumatoid Arthritis Society (NRAS), Maidenhead, UK; Department of Medicine, and the Division of Rheumatology, University of British Columbia, Vancouver; Arthritis Research Canada, Richmond, British Columbia; Institute for Work & Health; University of Toronto, Toronto; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Division of Rheumatology, Maastricht University Medical Center, Care and Public Health Research Institute (CAPHRI), Maastricht; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands; Department of Rehabilitation and Movement Science, University of Vermont, Burlington, Vermont, USA; Swiss Paraplegic Research, Nottwil, Switzerland; Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Carol Davila University of Medicine, Bucharest, Romania; School of Public Health and Community Medicine, University of New South Wales, Kensington, Australia.,S.M. Verstappen, PhD, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, and Arthritis Research UK/MRC Centre for Musculoskeletal Health and Work, University of Southampton; D. Lacaille, MDCM, FRCPC, MHSc, Department of Medicine, and the Division of Rheumatology, Department of Medicine, University of British Columbia, and Arthritis Research Canada; A. Boonen, MD, PhD, Division of Rheumatology, Maastricht University Medical Center, CAPHRI; R. Escorpizo, BSc, MSc, DPT, Department of Rehabilitation and Movement Science, University of Vermont, and Swiss Paraplegic Research; C. Hofstetter, OMERACT Patient Research Partner; A. Bosworth, MBE, OMERACT Patient Research Partner, NRAS; A. Leong, OMERACT Patient Research Partner; S. Leggett, MSc, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre; M.A. Gignac, PhD, Institute for Work & Health, and University of Toronto; J.K. Wallman, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology; M.M. Ter Wee, PhD, MSc, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, and Department of Rheumatology, Amsterdam Infection and Immunity Institute, Amsterdam Public Health; F. Berghea, MD, PhD, Carol Davila University of Medicine; M. Agaliotis, PhD, MSc, Australian Institute of Health Management Services, University of Tasmania; P. Tugwell, MD, MSc, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute; D. Beaton, PhD, Institute for Work & Health, and University of Toronto
| |
Collapse
|
26
|
McCormick N, Marra CA, Sadatsafavi M, Kopec JA, Aviña‐Zubieta JA. Excess Productivity Costs of Systemic Lupus Erythematosus, Systemic Sclerosis, and Sjögren's Syndrome: A General Population–Based Study. Arthritis Care Res (Hoboken) 2018; 71:142-154. [DOI: 10.1002/acr.23573] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2017] [Accepted: 04/03/2018] [Indexed: 11/10/2022]
Affiliation(s)
- Natalie McCormick
- Arthritis Research CanadaRichmond, and The University of British Columbia Vancouver British Columbia Canada
| | - Carlo A. Marra
- Arthritis Research Canada, Richmond, and The University of British Columbia, Vancouver, British Columbia, Canada, and University of Otago Dunedin New Zealand
| | | | - Jacek A. Kopec
- Arthritis Research CanadaRichmond, and The University of British Columbia Vancouver British Columbia Canada
| | - J. Antonio Aviña‐Zubieta
- Arthritis Research CanadaRichmond, and The University of British Columbia Vancouver British Columbia Canada
| |
Collapse
|
27
|
Abstract
Psoriatic arthritis (PsA) is a multifaceted disease, with a high impact on patients’ psychological and physical well-being. There is increasing recognition that assessment of both clinical aspects of disease and patient identified concerns, such as fatigue, work disability, and treatment satisfaction need to be addressed. Only then can we fully understand disease burden and make well-informed treatment decisions aimed at improving patients’ lives. In recent years, there has been much progress in the development of unidimensional and composite measures of disease activity, as well as questionnaires capturing the patient’s perspective in psoriatic disease. Despite these advances, there remains disagreement amongst clinicians as to which instruments should be used. As a consequence, they are yet to receive widespread implementation in routine clinical practice. This review aims to summarize currently available clinical and patient-derived assessment tools, which will provide clinicians with a practical and informative resource.
Collapse
|
28
|
Tamminga SJ, de Jong M, Frings-Dresen MHW, de Boer AGEM. The Quality of Working Life Questionnaire for Cancer Survivors: Sufficient responsiveness for use as a patient-reported outcome measurement. Eur J Cancer Care (Engl) 2018; 27:e12910. [DOI: 10.1111/ecc.12910] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Revised: 07/20/2018] [Accepted: 07/24/2018] [Indexed: 11/28/2022]
Affiliation(s)
- Sietske J. Tamminga
- Department: Coronel Institute of Occupational Health, Amsterdam Public Health Research Institute, Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands
| | - Merel de Jong
- Department: Coronel Institute of Occupational Health, Amsterdam Public Health Research Institute, Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands
| | - Monique H. W. Frings-Dresen
- Department: Coronel Institute of Occupational Health, Amsterdam Public Health Research Institute, Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands
| | - Angela G. E. M. de Boer
- Department: Coronel Institute of Occupational Health, Amsterdam Public Health Research Institute, Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands
| |
Collapse
|
29
|
Tillett W, Bojke L. Work Disability and the Cost-effectiveness of Drugs to Treat Rheumatic Diseases - Time for a New Dialogue? J Rheumatol 2018; 45:1075-1077. [PMID: 30068757 DOI: 10.3899/jrheum.180197] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- William Tillett
- Royal National Hospital for Rheumatic Diseases; and Department of Pharmacy and Pharmacology, University of Bath, Bath;
| | - Laura Bojke
- Centre for Health Economics, University of York, York, UK
| |
Collapse
|
30
|
Tanaka Y, Kameda H, Saito K, Kaneko Y, Tanaka E, Yasuda S, Tamura N, Fujio K, Fujii T, Kojima T, Anzai T, Hamada C, Fujino Y, Matsuda S, Kohsaka H. Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study. Arthritis Res Ther 2018; 20:151. [PMID: 30029613 PMCID: PMC6053758 DOI: 10.1186/s13075-018-1647-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2018] [Accepted: 06/18/2018] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Following the onset of rheumatoid arthritis (RA), patients experience a functional decline caused by various joint symptoms which affects their activities of daily living and can lead to reduced work productivity. We evaluated the effect of a 52-week treatment with tocilizumab by subcutaneous injection (TCZ-SC) among biologic-naive Japanese house workers (HWs) and paid workers (PWs) with RA in a real-world clinical practice. METHODS This multicenter, observational, prospective study enrolled 377 and 347 RA patients into TCZ-SC and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)-alone groups, respectively. The primary endpoint was the change in percentage of overall work impairment (OWI) among PWs at week 52 assessed using the Work Productivity and Activity Impairment Questionnaire (WPAI). Inverse probability of treatment weighting analyses were used to compare treatments. The Work Functioning Impairment Scale, disease activity, quality of life (QOL) measures, and safety were also assessed. RESULTS The weighted change in OWI from baseline for PWs was -18.9% (TCZ-SC group) and -19.0% (csDMARDs group) at week 52, without a significant between-group difference (adjusted treatment difference 0.1, 95% confidence interval (CI) -6.3 to 6.5; P = 0.978). Changes in WPAI activity impairment in the overall group (between-group difference -6.4, 95% CI -10.7 to -2.2; P = 0.003) and HWs (-9.5, 95% CI - 16.0 to -2.9; P = 0.005) were significantly better with TCZ-SC than with csDMARDs at week 52. TCZ-SC-treated HWs showed significant improvement in all QOL assessments (Frenchay Activities Index, EuroQol 5 Dimension (EQ-5D), Japanese Health Assessment Questionnaire Disability Index (HAQ-DI), and 6-item Kessler scale (K6)) at week 52; PWs did not show any between-group differences for these QOL measures. Disease activity (Disease Activity Score 28-erythrocyte sedimentation rate, Clinical Disease Activity Index, and Simplified Disease Activity Index) and QOL measures (EQ-5D, HAQ-DI, and K6) improved over time in the overall group. No new safety concerns were raised with TCZ-SC. CONCLUSIONS Despite the lack of differences in OWI between groups at week 52, the overall group (particularly HWs) receiving TCZ-SC in addition to csDMARDs showed significant improvements in activity impairment, disease activity, and QOL versus those receiving csDMARDs alone. This study may promote the evaluation of work productivity improvements in HWs and PWs by RA treatment.
Collapse
Affiliation(s)
- Yoshiya Tanaka
- University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka, 807-0804, Japan.
| | - Hideto Kameda
- Toho University, 2-22-36 Ohashi, Meguro-ku, Tokyo, 153-8515, Japan
| | - Kazuyoshi Saito
- University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka, 807-0804, Japan.,Tobata General Hospital, 1-3-33 Fukuryugi, Tobata-ku, Kitakyushu, Fukuoka, 804-0025, Japan
| | - Yuko Kaneko
- Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Eiichi Tanaka
- Tokyo Women's Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo, 162-0054, Japan
| | - Shinsuke Yasuda
- Hokkaido University, N15, W7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | - Naoto Tamura
- Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan
| | - Keishi Fujio
- The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8654, Japan
| | - Takao Fujii
- Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan
| | - Toshihisa Kojima
- Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
| | - Tatsuhiko Anzai
- EPS Corporation, 6-29 Shinogawamachi, Shinjuku-ku, Tokyo, 162-0814, Japan
| | - Chikuma Hamada
- Tokyo University of Science, 6-3-1 Niijuku, Katsuhika-ku, Tokyo, 125-8585, Japan
| | - Yoshihisa Fujino
- University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka, 807-0804, Japan
| | - Shinya Matsuda
- University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka, 807-0804, Japan
| | - Hitoshi Kohsaka
- Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| |
Collapse
|
31
|
Fautrel B, Alten R, Kirkham B, de la Torre I, Durand F, Barry J, Holzkaemper T, Fakhouri W, Taylor PC. Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. Rheumatol Int 2018; 38:935-947. [PMID: 29564549 PMCID: PMC5953992 DOI: 10.1007/s00296-018-4005-5] [Citation(s) in RCA: 59] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2017] [Accepted: 03/03/2018] [Indexed: 01/05/2023]
Abstract
Current guidelines for the management of rheumatoid arthritis (RA) recommend early treatment and a treat-to-target goal of remission or low disease activity. Over the past decade, this approach has been extremely successful in reducing disease activity and joint damage in patients with RA. At the same time, however, overall patient perception of well-being appears to have decreased with respect to outcome measures considered important by patients themselves, such as pain, fatigue, physical function and quality of life. The timely and effective use of patient-reported outcomes (PROs) could encourage physicians to focus more on the impact of RA on patients and how patients are feeling. This in turn would facilitate shared decision making between patients and physicians, ultimately leading to a more patient-centered approach and improved patient care. Indeed, PROs provide information about individual patients that complements information provided by physical assessment and composite scores, and can also be used to guide patient care, such as determining whether a clinic visit is needed or whether treatment modifications are necessary. This is particularly important for patients who do not achieve the aspirational target of remission or low disease activity with pharmacological treatment. A number of validated PRO questionnaires are available, but how and which PROs should be incorporated into rheumatology clinical practice as part of the decision-making process is still controversial. Combining PROs with technology, such as computer adaptive tests, electronic PRO systems, web-based platforms and patient dashboards, could further aid PRO integration into daily rheumatology clinical practice.
Collapse
Affiliation(s)
- Bruno Fautrel
- Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Universités, UPMC Universitaire Paris 06, Paris, France
- Department of Rheumatology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Rieke Alten
- Schlosspark-Klinik University Medicine, 14059, Berlin, Germany
| | - Bruce Kirkham
- Department of Rheumatology, Guys and St Thomas' NHS Trust, Great Maze Pond, London, SE1 9RT, UK
| | | | | | - Jane Barry
- Eli Lilly and Company, Basingstoke, Hampshire, UK
| | | | - Walid Fakhouri
- Eli Lilly and Company, Indianapolis, IN, USA
- Eli Lilly and Company, Basingstoke, Hampshire, UK
| | - Peter C Taylor
- Botnar Research Centre, NDORMS, University of Oxford, Oxford, UK.
| |
Collapse
|
32
|
The Role of Patient-Reported Outcomes in Systemic Lupus Erythematosus. CURRENT TREATMENT OPTIONS IN RHEUMATOLOGY 2017. [DOI: 10.1007/s40674-017-0079-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
33
|
Tunis SR, Maxwell LJ, Graham ID, Shea BJ, Beaton DE, Bingham CO, Brooks P, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March LM, Simon LS, Singh JA, Strand V, Wells GA, Tugwell P. Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets. J Rheumatol 2017; 44:1551-1559. [PMID: 28765256 DOI: 10.3899/jrheum.161273] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/31/2017] [Indexed: 12/30/2022]
Abstract
OBJECTIVE While there has been substantial progress in the development of core outcomes sets, the degree to which these are used by researchers is variable. We convened a special workshop on knowledge translation at the Outcome Measures in Rheumatology (OMERACT) 2016 with 2 main goals. The first focused on the development of a formal knowledge translation framework and the second on promoting uptake of recommended core outcome domain and instrument sets. METHODS We invited all 189 OMERACT 2016 attendees to the workshop; 86 attended, representing patient research partners (n = 15), healthcare providers/clinician researchers (n = 52), industry (n = 4), regulatory agencies (n = 4), and OMERACT fellows (n = 11). Participants were given an introduction to knowledge translation and were asked to propose and discuss recommendations for the OMERACT community to (1) strengthen stakeholder involvement in the core outcome instrument set development process, and (2) promote uptake of core outcome sets with a specific focus on the potential role of post-regulatory decision makers. RESULTS We developed the novel "OMERACT integrated knowledge translation" framework, which formalizes OMERACT's knowledge translation strategies. We produced strategies to improve stakeholder engagement throughout the process of core outcome set development and created a list of creative and innovative ways to promote the uptake of OMERACT's core outcome sets. CONCLUSION The guidance provided in this paper is preliminary and is based on the views of the participants. Future work will engage OMERACT groups, "post-regulatory decision makers," and a broad range of different stakeholders to identify and evaluate the most useful methods and processes, and to revise guidance accordingly.
Collapse
Affiliation(s)
- Sean R Tunis
- From the Center for Medical Technology Policy; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Cochrane Musculoskeletal, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Montigny-le-Bretonneux; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute, Amsterdam, the Netherlands.,IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN #143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity.,S.R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy; L.J. Maxwell, PhD, Cochrane Musculoskeletal, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; I.D. Graham, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; B.J. Shea, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; D.E. Beaton, BScOT, PhD, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P. Brooks, MD, FRACP, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; L.S. Simon, MD, Co-managing Director of SDG LLC; J.A. Singh, MD, MPH, Professor of Medicine and Epidemiology, University of Alabama at Birmingham, and Staff Physician, Birmingham Veterans Affairs Medical Center; V. Strand, MD, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa
| | - Lara J Maxwell
- From the Center for Medical Technology Policy; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Cochrane Musculoskeletal, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Montigny-le-Bretonneux; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute, Amsterdam, the Netherlands. .,IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN #143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity. .,S.R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy; L.J. Maxwell, PhD, Cochrane Musculoskeletal, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; I.D. Graham, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; B.J. Shea, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; D.E. Beaton, BScOT, PhD, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P. Brooks, MD, FRACP, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; L.S. Simon, MD, Co-managing Director of SDG LLC; J.A. Singh, MD, MPH, Professor of Medicine and Epidemiology, University of Alabama at Birmingham, and Staff Physician, Birmingham Veterans Affairs Medical Center; V. Strand, MD, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa.
| | - Ian D Graham
- From the Center for Medical Technology Policy; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Cochrane Musculoskeletal, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Montigny-le-Bretonneux; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute, Amsterdam, the Netherlands.,IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN #143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity.,S.R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy; L.J. Maxwell, PhD, Cochrane Musculoskeletal, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; I.D. Graham, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; B.J. Shea, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; D.E. Beaton, BScOT, PhD, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P. Brooks, MD, FRACP, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; L.S. Simon, MD, Co-managing Director of SDG LLC; J.A. Singh, MD, MPH, Professor of Medicine and Epidemiology, University of Alabama at Birmingham, and Staff Physician, Birmingham Veterans Affairs Medical Center; V. Strand, MD, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa
| | - Beverley J Shea
- From the Center for Medical Technology Policy; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Cochrane Musculoskeletal, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Montigny-le-Bretonneux; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute, Amsterdam, the Netherlands.,IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN #143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity.,S.R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy; L.J. Maxwell, PhD, Cochrane Musculoskeletal, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; I.D. Graham, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; B.J. Shea, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; D.E. Beaton, BScOT, PhD, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P. Brooks, MD, FRACP, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; L.S. Simon, MD, Co-managing Director of SDG LLC; J.A. Singh, MD, MPH, Professor of Medicine and Epidemiology, University of Alabama at Birmingham, and Staff Physician, Birmingham Veterans Affairs Medical Center; V. Strand, MD, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa
| | - Dorcas E Beaton
- From the Center for Medical Technology Policy; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Cochrane Musculoskeletal, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Montigny-le-Bretonneux; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute, Amsterdam, the Netherlands.,IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN #143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity.,S.R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy; L.J. Maxwell, PhD, Cochrane Musculoskeletal, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; I.D. Graham, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; B.J. Shea, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; D.E. Beaton, BScOT, PhD, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P. Brooks, MD, FRACP, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; L.S. Simon, MD, Co-managing Director of SDG LLC; J.A. Singh, MD, MPH, Professor of Medicine and Epidemiology, University of Alabama at Birmingham, and Staff Physician, Birmingham Veterans Affairs Medical Center; V. Strand, MD, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa
| | - Clifton O Bingham
- From the Center for Medical Technology Policy; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Cochrane Musculoskeletal, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Montigny-le-Bretonneux; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute, Amsterdam, the Netherlands.,IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN #143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity.,S.R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy; L.J. Maxwell, PhD, Cochrane Musculoskeletal, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; I.D. Graham, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; B.J. Shea, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; D.E. Beaton, BScOT, PhD, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P. Brooks, MD, FRACP, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; L.S. Simon, MD, Co-managing Director of SDG LLC; J.A. Singh, MD, MPH, Professor of Medicine and Epidemiology, University of Alabama at Birmingham, and Staff Physician, Birmingham Veterans Affairs Medical Center; V. Strand, MD, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa
| | - Peter Brooks
- From the Center for Medical Technology Policy; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Cochrane Musculoskeletal, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Montigny-le-Bretonneux; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute, Amsterdam, the Netherlands.,IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN #143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity.,S.R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy; L.J. Maxwell, PhD, Cochrane Musculoskeletal, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; I.D. Graham, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; B.J. Shea, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; D.E. Beaton, BScOT, PhD, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P. Brooks, MD, FRACP, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; L.S. Simon, MD, Co-managing Director of SDG LLC; J.A. Singh, MD, MPH, Professor of Medicine and Epidemiology, University of Alabama at Birmingham, and Staff Physician, Birmingham Veterans Affairs Medical Center; V. Strand, MD, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa
| | - Philip G Conaghan
- From the Center for Medical Technology Policy; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Cochrane Musculoskeletal, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Montigny-le-Bretonneux; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute, Amsterdam, the Netherlands.,IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN #143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity.,S.R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy; L.J. Maxwell, PhD, Cochrane Musculoskeletal, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; I.D. Graham, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; B.J. Shea, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; D.E. Beaton, BScOT, PhD, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P. Brooks, MD, FRACP, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; L.S. Simon, MD, Co-managing Director of SDG LLC; J.A. Singh, MD, MPH, Professor of Medicine and Epidemiology, University of Alabama at Birmingham, and Staff Physician, Birmingham Veterans Affairs Medical Center; V. Strand, MD, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa
| | - Maria Antonietta D'Agostino
- From the Center for Medical Technology Policy; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Cochrane Musculoskeletal, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Montigny-le-Bretonneux; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute, Amsterdam, the Netherlands.,IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN #143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity.,S.R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy; L.J. Maxwell, PhD, Cochrane Musculoskeletal, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; I.D. Graham, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; B.J. Shea, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; D.E. Beaton, BScOT, PhD, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P. Brooks, MD, FRACP, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; L.S. Simon, MD, Co-managing Director of SDG LLC; J.A. Singh, MD, MPH, Professor of Medicine and Epidemiology, University of Alabama at Birmingham, and Staff Physician, Birmingham Veterans Affairs Medical Center; V. Strand, MD, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa
| | - Maarten P de Wit
- From the Center for Medical Technology Policy; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Cochrane Musculoskeletal, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Montigny-le-Bretonneux; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute, Amsterdam, the Netherlands.,IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN #143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity.,S.R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy; L.J. Maxwell, PhD, Cochrane Musculoskeletal, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; I.D. Graham, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; B.J. Shea, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; D.E. Beaton, BScOT, PhD, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P. Brooks, MD, FRACP, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; L.S. Simon, MD, Co-managing Director of SDG LLC; J.A. Singh, MD, MPH, Professor of Medicine and Epidemiology, University of Alabama at Birmingham, and Staff Physician, Birmingham Veterans Affairs Medical Center; V. Strand, MD, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa
| | - Laure Gossec
- From the Center for Medical Technology Policy; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Cochrane Musculoskeletal, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Montigny-le-Bretonneux; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute, Amsterdam, the Netherlands.,IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN #143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity.,S.R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy; L.J. Maxwell, PhD, Cochrane Musculoskeletal, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; I.D. Graham, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; B.J. Shea, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; D.E. Beaton, BScOT, PhD, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P. Brooks, MD, FRACP, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; L.S. Simon, MD, Co-managing Director of SDG LLC; J.A. Singh, MD, MPH, Professor of Medicine and Epidemiology, University of Alabama at Birmingham, and Staff Physician, Birmingham Veterans Affairs Medical Center; V. Strand, MD, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa
| | - Lyn M March
- From the Center for Medical Technology Policy; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Cochrane Musculoskeletal, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Montigny-le-Bretonneux; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute, Amsterdam, the Netherlands.,IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN #143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity.,S.R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy; L.J. Maxwell, PhD, Cochrane Musculoskeletal, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; I.D. Graham, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; B.J. Shea, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; D.E. Beaton, BScOT, PhD, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P. Brooks, MD, FRACP, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; L.S. Simon, MD, Co-managing Director of SDG LLC; J.A. Singh, MD, MPH, Professor of Medicine and Epidemiology, University of Alabama at Birmingham, and Staff Physician, Birmingham Veterans Affairs Medical Center; V. Strand, MD, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa
| | - Lee S Simon
- From the Center for Medical Technology Policy; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Cochrane Musculoskeletal, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Montigny-le-Bretonneux; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute, Amsterdam, the Netherlands.,IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN #143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity.,S.R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy; L.J. Maxwell, PhD, Cochrane Musculoskeletal, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; I.D. Graham, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; B.J. Shea, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; D.E. Beaton, BScOT, PhD, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P. Brooks, MD, FRACP, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; L.S. Simon, MD, Co-managing Director of SDG LLC; J.A. Singh, MD, MPH, Professor of Medicine and Epidemiology, University of Alabama at Birmingham, and Staff Physician, Birmingham Veterans Affairs Medical Center; V. Strand, MD, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa
| | - Jasvinder A Singh
- From the Center for Medical Technology Policy; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Cochrane Musculoskeletal, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Montigny-le-Bretonneux; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute, Amsterdam, the Netherlands.,IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN #143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity.,S.R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy; L.J. Maxwell, PhD, Cochrane Musculoskeletal, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; I.D. Graham, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; B.J. Shea, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; D.E. Beaton, BScOT, PhD, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P. Brooks, MD, FRACP, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; L.S. Simon, MD, Co-managing Director of SDG LLC; J.A. Singh, MD, MPH, Professor of Medicine and Epidemiology, University of Alabama at Birmingham, and Staff Physician, Birmingham Veterans Affairs Medical Center; V. Strand, MD, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa
| | - Vibeke Strand
- From the Center for Medical Technology Policy; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Cochrane Musculoskeletal, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Montigny-le-Bretonneux; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute, Amsterdam, the Netherlands.,IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN #143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity.,S.R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy; L.J. Maxwell, PhD, Cochrane Musculoskeletal, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; I.D. Graham, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; B.J. Shea, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; D.E. Beaton, BScOT, PhD, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P. Brooks, MD, FRACP, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; L.S. Simon, MD, Co-managing Director of SDG LLC; J.A. Singh, MD, MPH, Professor of Medicine and Epidemiology, University of Alabama at Birmingham, and Staff Physician, Birmingham Veterans Affairs Medical Center; V. Strand, MD, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa
| | - George A Wells
- From the Center for Medical Technology Policy; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Cochrane Musculoskeletal, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Montigny-le-Bretonneux; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute, Amsterdam, the Netherlands.,IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN #143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity.,S.R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy; L.J. Maxwell, PhD, Cochrane Musculoskeletal, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; I.D. Graham, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; B.J. Shea, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; D.E. Beaton, BScOT, PhD, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P. Brooks, MD, FRACP, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; L.S. Simon, MD, Co-managing Director of SDG LLC; J.A. Singh, MD, MPH, Professor of Medicine and Epidemiology, University of Alabama at Birmingham, and Staff Physician, Birmingham Veterans Affairs Medical Center; V. Strand, MD, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa
| | - Peter Tugwell
- From the Center for Medical Technology Policy; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Cochrane Musculoskeletal, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Montigny-le-Bretonneux; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute, Amsterdam, the Netherlands.,IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN #143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity.,S.R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy; L.J. Maxwell, PhD, Cochrane Musculoskeletal, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; I.D. Graham, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; B.J. Shea, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; D.E. Beaton, BScOT, PhD, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P. Brooks, MD, FRACP, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; L.S. Simon, MD, Co-managing Director of SDG LLC; J.A. Singh, MD, MPH, Professor of Medicine and Epidemiology, University of Alabama at Birmingham, and Staff Physician, Birmingham Veterans Affairs Medical Center; V. Strand, MD, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa
| |
Collapse
|
34
|
[Standardized outcome parameters]. Z Rheumatol 2016; 75:620-3. [PMID: 27379737 DOI: 10.1007/s00393-016-0127-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|